External Link

Disclaimer: You are now leaving www.beiresources.org and are going to a website that is not operated by BEI Resources. We are not responsible for the content or availability of linked sites.

ABOUT THIRD PARTY LINKS ON OUR SITE:
BEI Resources offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links, you will leave the BEI Resources website and will be redirected to another site. These sites are not under the control of BEI Resources. BEI Resources is not responsible for the content of linked third party websites. We are neither an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information. Please read third party privacy and security policies closely as these may be different than BEI Resources policies. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

  
Skip to main content
BEI Resources Web Portal
Shopping Cart     Advanced Search   Login
  • Home
  • Catalog
    • Antimicrobial Search
    • Tuberculosis Mutant Search
      • TARGET
    • NARSA
    • Vector Resources
    • Suggest a Reagent
    • New Reagents
    • Select Agent Requests
    • Coming Soon
    • Resource Links
  • Deposits
    • Deposit Information
    • Deposit Forms
    • Deposit Release Policy
  • Register
    • Registration Information
    • Registration Forms
    • Upgrade Registration
    • Eligibility
    • Registration FAQs
  • MR4
    • Program
    • Anopheles Program
      • Training & Methods
      • Anopheles
      • Custom Items
      • Chromosomes
      • Obtaining Mosqs.
    • Special Order (Non-Catalog) Reagents
      • Microscopy Slides
      • Custom Mosquitoes
      • Sequenced Library Clones
      • Other Custom Reagents
    • Reagent Data
    • Protocols and Publications
    • Malaria Links
      • Foundations and Organizations
      • Laboratories and Protocols
      • Malaria and Tropical Disease Journal
      • Malaria Research Resources
      • Molecular Reference Databases
  • About
    • BEI Resources
    • Human Microbiome Project
    • MR4
    • Publications
    • Contact Us
    • Knowledge Base
select
  • Bacteria Select Agents and Near Neighbor
  • Other Bacteria
  • Dalrymple-Peters USAMRIID Antibodies
  • Ferret Reagents
  • Filariasis Resources
  • Food and Waterborne
  • Fungi
  • Human Microbiome Project
  • Leprosy Research Support
  • Influenza Resources
  • Innate Immunity
  • MR4-Malaria Resources
  • Mycoplasmas
  • Mycobacterium
  • NARSA
  • Nosocomial Infections
  • Parasitic Protists
  • PFGRC Center Clones
  • Proteomics Research Centers
  • Public Health Emergency Materials
  • Rickettsiales
  • Sexually Transmitted Agents
  • Schistosome Resource Centers
  • SARS-CoV-2
  • Spirochetes
  • Toxin or Toxoids
  • Vector Resources
  • Viral Select Agents
  • Viruses
select
  • Abrin
  • Acanthamoeba sp.
  • Acinetobacter sp.
  • Anaplasma sp.
  • Arboviruses
  • Arenaviruses
  • Arthropod Vectors
  • Aspergillus sp.
  • Babesia sp.
  • Bacillus sp.
  • Bartonella sp.
  • Bacteroides
  • Borrelia sp.
  • Bordetella sp.
  • Brucella sp.
  • Brugia sp.
  • Burkholderia sp.
  • Campylobacter
  • Candida sp.
  • Cavia porcellus
  • Chikungunya
  • Chlamydia sp.
  • Clostridium sp.
  • Coccidioides sp.
  • Coronaviruses
  • Coxiella sp.
  • Cryptococcus sp.
  • Cryptosporidium
  • Dengue
  • Ehrlichia sp.
  • Encephalitozoon sp.
  • Ebola
  • Entamoeba sp.
  • Enterococcus sp.
  • Enterovirus sp.
  • Escherichia sp.
  • Filarial Worms
  • Francisella sp.
  • Giardia sp.
  • Hepatitis
  • Hantaviruses
  • Human Microbiome
  • Influenza
  • Interferons
  • Klebsiella
  • Langat Virus
  • Leishmania
  • Leptospira sp.
  • Listeria sp.
  • Malaria Related sp.
  • Marburg
  • Measles/Mumps
  • Mosquitoes
  • Mycobacterium leprae
  • Mycobacterium sp.
  • Mycobacterium tuberculosis
  • Mycoplasma
  • Neisseria sp.
  • Onchocerca volvulus
  • Paramyxoviruses
  • Plasmodium sp.
  • Pox Viruses
  • Pseudomonas sp.
  • Reduviids
  • Ricin Toxin
  • Rickettsias
  • RSV
  • Salmonella sp.
  • Sand Flies
  • SARS-CoV-2
  • Schistosomes
  • Shiga Toxin
  • Shigella sp.
  • Snails
  • Staphylococcus sp.
  • Streptococcus sp.
  • Ticks
  • Toxins
  • Toxoplasma sp.
  • Trypanosoma
  • Tsetse Fly
  • Vibrio sp.
  • West Nile Virus
  • Wolbachia sp.
  • Wuchereria bancrofti
  • Yellow Fever Virus
  • Yersinia sp.
  • Zika virus


Menu
  • Home
  • Catalog
    • Antimicrobial Search
    • Tuberculosis Mutant Search
      • TARGET
    • NARSA
    • Vector Resources
    • Suggest a Reagent
    • New Reagents
    • Select Agent Requests
    • Coming Soon
    • Resource Links
  • Deposits
    • Deposit Information
    • Deposit Forms
    • Deposit Release Policy
  • Register
    • Registration Information
    • Registration Forms
    • Upgrade Registration
    • Eligibility
    • Registration FAQs
  • MR4
    • Program
    • Anopheles Program
      • Training & Methods
      • Anopheles
      • Custom Items
      • Chromosomes
      • Obtaining Mosqs.
    • Special Order (Non-Catalog) Reagents
      • Microscopy Slides
      • Custom Mosquitoes
      • Sequenced Library Clones
      • Other Custom Reagents
    • Reagent Data
    • Protocols and Publications
    • Malaria Links
      • Foundations and Organizations
      • Laboratories and Protocols
      • Malaria and Tropical Disease Journal
      • Malaria Research Resources
      • Molecular Reference Databases
  • About
    • BEI Resources
    • Human Microbiome Project
    • MR4
    • Publications
    • Contact Us
    • Knowledge Base
Administration »  BEI Highlights
Information
Information
Highlights

SARS-CoV-2 Variant Table

 

* Please see the appendix section in the COA for each virus lot on variant analysis on the specific virus stock.
 BEI #   Isolate Description  Alternate Name  Lineage  GISAID
 Clade
 GISAID ID  AA Substitutions per GISAID*
 NR-53944   hCoV-19/Scotland/CVR837/2020   CVR-GLA-1 B.1.5 G  EPI_ISL_461705  Spike D614G, NSP12, P323L
 NR-53945  hCoV-19/Scotland/CVR2224/2020   CVR-GLA-2 B.1.222 G  EPI_ISL_448167  Spike D614G, Spike N439K, NSP12 P323L
 NR-53953  hCoV-19/Denmark/DCGC-3024/2020   SARS-CoV-2/hu/DK/CL-5/1   B.1.1.298  GR  EPI_ISL_616802   Spike D614G, Spike H69del, Spike I692V, Spike M1229I, Spike V70del, Spike Y453F, N G204R, N R203K, N S194L, NS3 H182Y, NSP1 M85del, NSP3 N1263del, NSP12 P323L, NSP12 T739I, NSP15 T112I
 NR-54000  hCoV-19/England/204820464/2020   UK/VUI/3/2020    B.1.1.7  GR  EPI_ISL_683466  Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y145del, N D3L, N G204R, N R203K, N S235F, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP3 A1305V, NSP3 I1412T, NSP3 T183I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 K460R, NSP14 E347G
 NR-54008  hCoV-19/South Africa/KRISP-EC-K005321/2020   501Y.V2.HVdelta or
 HVdF002 
B.1.351 GH  EPI_ISL_678570  Spike A243del, Spike A701V, Spike D80A, Spike D215G, Spike D614G, Spike E484K, Spike K417N, Spike L242del, Spike L244del, Spike N501Y, E P71L, N T205I, NS3 Q57H, NS3 S171L, NSP2 T85I, NSP3 K837N, NSP5 K90R, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L
 NR-54009  hCoV-19/South Africa/KRISP-K005325/2020   501Y.V2.HV  B.1.351 GH  EPI_ISL_678615 Spike A243del, Spike A701V, Spike D80A, Spike D215G, Spike D614G, Spike E484K, Spike K417N, Spike L18F, Spike L242del, Spike L244del, Spike N501Y, E P71L, N T205I, NS3 Q57H, NS3 S171L, NS3 W131L, NS7a V93F, NSP2 T85I, NSP3 K837N, NSP5 K90R, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L
 NR-54011  hCoV-19/USA/CA_CDC_5574/2020   hCoV-19/USA/CA-
 SEARCH-5574/2020 
 B.1.1.7  GR  EPI_ISL_751801 Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y145del, M V70L, N D3L, N G204R, N R203K, N S235F, NS3 T223I, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP3 I1412T, NSP3 T183I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 A454V, NSP13 K460R
 NR-54981  hCoV-19/Japan/TY7-501/2021   TY7-501, hCoV-19/Japan/
 IC-0562/2021 (P0)
 P.1.
(or 20J/501Y.V3) 
 GR EPI_ISL_792681 and EPI_ISL_833366 (passage 1 in Vero E6 /TMPRSS2*
*contains a G181V mutation compared with sequence from original sample.
*Spike D138Y, Spike D614G, Spike E484K, Spike G181V, Spike H655Y, Spike K417T, Spike L18F, Spike N501Y, Spike P26S, Spike R190S, Spike T20N, Spike T1027I, Spike V1176F, N G204R, N P80R, N R203K, NS3 S253P, NS8 E92K, NSP3 K977Q, NSP3 S370L, NSP3 T186A, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 E341D
 NR-54982  hCoV-19/Japan/TY7-503/2021    TY7-503, hCoV-19/Japan/
 IC-0564/2021 (P0)
 P.1.
(or 20J/501Y.V3)
 GR EPI_ISL_792683 and EPI_ISL_877769 (passage 1 in Vero E6 /TMPSS2*)
*contains a F184V mutation compared with sequence from original sample.
*Spike D138Y, Spike D614G, Spike E484K, Spike H655Y, Spike K417T, Spike L18F, Spike N501Y, Spike P26S, Spike R190S, Spike T20N, Spike T1027I, Spike V1176F, N G204R, N P80R, N R203K, NS3 S253P, NS8 E92K, NSP3 K977Q, NSP3 S370L, NSP6 F108del, NSP6 F184V, NSP6 G107del, NSP6 S106del, NSP12 P323L, NSP13 E341D
 NR-54985  hCoV-19/USA/MD-HP12112/2021     B.1.1.207   GR  EPI_ISL_791427 Spike D614G, Spike E484K, Spike P681H, M V70F, N G204R, N R203K, NS3 A143S, NS3 V202L, NSP2 S248G, NSP3 H249Y, NSP3 M196T, NSP6 A2V, NSP12 P323L, NSP13 L122S
 NR-54986  hCoV-19/USA/MD-HP12155/2020      B.1.1.4  GR  EPI_ISL_791346 Spike D614G, Spike E484K, Spike G769V, Spike W152L, M F28L, N G204R, N Q418H, N R203K, N S187L, NSP2 H145Q, NSP3 P985L, NSP6 L37F, NSP12 P323L, NSP13 G439R, NSP14 P412H, NSP15 P118S
 NR-54987  hCoV-19/USA/MD-HP01101/2021      B.1.1.7  GR  EPI_ISL_825013 Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y144del, N D3L, N G204R, N R203K, N S235F, NS8 K68stop, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP3 I1412T, NSP3 T183I, NSP6 F108del, NSP6 G107del, NSP6 S106del, NSP12 P227L, NSP12 P323L, NSP14 P451S

 


Unusual Gram-Negative Bacteria
Highlights

The genus Flavobacterium has undergone several taxonomic shifts since it was created nearly 100 years ago, beginning with the separation of a number of pathogenic species into a new genus, Chryseobacterium.1 Further reclassification occurred with the naming of genus Elizabethkingia into which several Chryseobacterium were moved, including the pathogenic species E. meningoseptica (formerly Chryseobacterium meningosepticum; originally Flavobacterium meningosepticum) and E. miricola.2 Recent genomic analysis of unidentified isolates resembling the two genera, as well as a review of the four genomospecies of Elizabethkingia, have resulted in the naming of new, novel species of Chryseobacterium and Elizabethkingia.1,2 Chryseobacterium underwent an even more recent taxonomic reorganization following the comparison of amino acid identity among type strains, leading to the division of the Chryseobacterium genus into four different genera with Epilithonimonas, Kaistella and Halpernia gen. nov.3 Many of these reclassifications involved the renaming of historical isolates and type strains, many of which were recently deposited to BEI Resources.

Chryseobacterium spp. and Elizabethkingia spp. are Gram-negative environmental bacteria found in soil and water worldwide. Though infections in humans are rare, an average of 5-to-10 cases occur per state each year in the United States, often resulting in small healthcare-related outbreaks, such as the E. anopheles outbreak in Wisconsin in 2016.4

BEI Resources No.       Product Description
NR-51489 Chryseobacterium bernardetii, Strain G0229
NR-51492 Elizabethkingia bruuniana, Strain G0146
NR-51493 Elizabethkingia occulta, Strain G4070
NR-51494 Elizabethkingia ursingii, Strain G4122
NR-51490 Mycobacterium ulcerans, Strain Benin UB 343/08 - Coming Soon
NR-51491 Chryseobacterium nakagawei, Strain G0041 – Coming Soon
NR-51495 Epilithonimonas vandammei, Strain F5649 – Coming Soon
NR-51496 Kaistella carnis, Strain G0081 
NR-51497 Kaistella daneshvariae, Strain H3001 

 

References:

  1. Holmes, B., A. G. Steigerwalt and A. C. Nicholson. “DNA-DNA Hybridization Study of Strains of Chryseobacterium, Elizabethkingia and Empedobacter and of Other Usually Indole-Producing Non-Fermenters of CDC Groups IIc, IIe, IIh and IIi, Mostly from Human Clinical Sources, and Proposals of Chryseobacterium bernardetii sp. nov., Chryseobacterium carnis sp. nov., Chryseobacterium lactis sp. nov., Chryseobacterium nakagawai sp. nov. and Chryseobacterium taklimakanense comb. nov.” Int. J. Syst. Evol. Microbiol. 63 (2013):  4639-4662.  PubMed:  23934253.
  2. Nicholson, A. C., et al. “Revisiting the Taxonomy of the Genus Elizabethkingia Using Whole-Genome Sequencing, Optical Mapping, and MALDI-TOF, Along with Proposal of Three Novel Elizabethkingia species: Elizabethkingia bruuniana sp. nov., Elizabethkingia ursingii sp. nov., and Elizabethkingia occulta sp. nov.” Antonie Van Leeuwenhoek 111 (2018):  55-72.  PubMed:  28856455.
  3. Nicholson, A. C., et al. “Division of the genus Chryseobacterium: Observation of Discontinuities in Amino Acid Identity Values, a Possible Consequence of Major Extinction Events, Guides Transfer of Nine Species to the Genus Epilithonimonas, Eleven Species to the Genus Kaistella, and Three Species to the Genus Halpernia gen. nov., with Description of Kaistella daneshvariae sp. nov. and Epilithonimonas vandammei sp. nov. Derived from Clinical Specimens.” Int. J. Syst. Evol. Microbiol. 70 (2020):  4432-4450.  PubMed:  32735208.
  4. “Elizabethkingia.”  Centers for Disease Control and Prevention, U.S. Department of Health and Human Services,  https://www.cdc.gov/elizabethkingia/index.html.

Image:  Transmission electron microscopic image of Elizabethkingia anophelis bacteria (CDC/Cynthia Goldsmith)


Multidrug-Resistant Candida auris
Highlights

Candida auris is an emerging multidrug-resistant pathogenic yeast, which causes invasive infections and outbreaks in nosocomial settings resulting in high mortality. Since it was first described in 2009, C. auris has been isolated in over 30 countries on 6 continents, with the earliest known isolate from 1996 discovered during a retrospective review of unidentified yeasts.1,2,3

C. auris has a strong phylogeographic structure comprising four distinct clades, South Asia, East Asia, South Africa and South America, separated by tens of thousands of SNPs, with smaller clusters identified in some clades.3 This high level of relatedness and low genetic diversity within clades suggests clades emerged independently and near-simultaneously in four distinct locations rather than a single spread.1,3

Clinical isolates from a hospital in Pakistan, the site of a 2014 C. auris outbreak5, have been deposited to BEI Resources and represent bloodstream infections with varied antifungal resistance profiles to azole and polyene drug classes. More information about the resistance profiles of these isolates is available in the BEI Resources Antimicrobial Database and on the individual product web pages and documentation

BEI Resources No.       Product Description
NR-52713 Candida auris, Strain AKU-2017-385
NR-52714 Candida auris, Strain AKU-2018-257
NR-52715 Candida auris, Strain AKU-2019-111

 

References:

  1. Forsberg, K., et al. “Candida auris:  The Recent Emergence of a Multidrug-Resistant Fungal Pathogen.” Med. Mycol. 57 (2019): 1-12.  PubMed:  30085270.
  2. Kean, R. and G. Ramage. “Combined Antifungal Resistance and Biofilm Tolerance: The Global Threat of Candida auris.” mSphere 4 (2019): e00458-19.  PubMed:  31366705.
  3. Lockhart, S. R., et al. “Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses.” Clin. Infect. Dis. 64 (2017): 134-140. PubMed: 27988485.
  4. Sayeed, M. A., et al. “Clinical Spectrum and Factors Impacting Outcome of Candida auris: A Single Center Study from Pakistan.” BMC Infect. Dis. 19 (2019): 384. PubMed:  31060514.

Image:  Medical illustration of Candida auris fungal organisms (CDC/Medical Illustrator: Stephanie Rossow)


Black Fly Life Stages Through A Partnership with the University of Georgia
Highlights

BEI Resources is pleased to announce the upcoming availability of black flies through a partnership with the University of Georgia Black Fly Rearing and Bioassay Laboratory, which has operated the only known colony of black flies (Diptera: Simuliidae) for over 20 years. Since its establishment, the Simulium vittatum colony (Simulium vittatum cytospecies IS-7) has been used for a variety of research projects, including vector transmission studies, environmental monitoring, vector control and larval feeding studies. Rearing protocols have been designed to operate the black fly colony at maximum productivity to produce a standardized test subject and preserve colony vigor. An advantage of Simulium vittatum cytospecies IS-7 is that they can deposit their first batch of eggs without a blood meal. Consequently, no animal resources are required to maintain the colony.

The laboratory continues to conduct and collaborate in a wide range of research projects, providing all stages of the black fly life cycle to collaborating laboratories. Current research conducted in the laboratory involves larvicidal efficacy evaluations, topical repellent evaluations and growth studies related to climate change.

More information on the Simulium vittatum Black Fly Colony will be available in the BEI Resources Vector Resource Catalog and on individual product web pages and documentation.

BEI Resources No.       Product Description 
NR-53890 Simulium vittatum, cytospecies IS-7, Live Eggs
NR-53891 Simulium vittatum, cytospecies IS-7, Live Larvae
NR-53892 Simulium vittatum, cytospecies IS-7, Live Pupae
NR-53893 Simulium vittatum, cytospecies IS-7, Live Adult
NR-53894 Simulium vittatum, cytospecies IS-7, Preserved Eggs
NR-53895 Simulium vittatum, cytospecies IS-7, Preserved Larvae
NR-53896 Simulium vittatum, cytospecies IS-7, Preserved Pupae
NR-53897 Simulium vittatum, cytospecies IS-7, Preserved Adult
NR-53898 Simulium vittatum, cytospecies IS-7, Genomic DNA
   

Image:  Black Fly bite (UGA, Jena Johnson)


Mycobacterium ulcerans - Now Available
Highlights

The extensive collection of Mycobacterium species available from BEI Resources continues to grow with the addition of M. ulcerans, the cause of a neglected tropical disease known as Buruli ulcer that causes cutaneous lesions and osteomyelitis.1,2,3 M. ulcerans has been identified in 33 countries worldwide, most commonly in Africa, and typically occurs in wetland and tropical regions and in areas with recent environmental change.2 M. ulcerans contains a virulence plasmid encoding for the production of mycolactone, a macrocyclic polyketide toxin with cytotoxic and immunosuppressive activity.

The available and upcoming isolates were collected from clinical cases of Buruli ulcer in Benin, where over 6,000 Buruli ulcer cases were reported between 2006 and 2015.4

BEI Resources No.       Product Description
NR-51701 Mycobacterium ulcerans, Strain S4018
NR-50137 Mycobacterium ulcerans, Strain Benin UB 502/08 - In Pre-Production
NR-50138 Mycobacterium ulcerans, Strain Benin UB 343/08 - In Pre-Production
NR-50139 Mycobacterium ulcerans, Strain Benin UB 609/08 - In Pre-Production

 

References:

  1. Röltgen, K., T. P. Stinear and G. Pluschke. “The Genome, Evolution and Diversity of Mycobacterium ulcerans.” Infect. Genet. Evol. 12 (2012): 522-529. PubMed: 22306192.
  2. Merritt, R. W., et al. “Ecology and Transmission of Buruli Ulcer Disease: A Systematic Review.” PloS Negl.Trop. Dis. 4 (2010): e911. PubMed: 21179505.
  3. Pommelet, V., et al. “Findings in Patients from Benin with Osteomyelitis and Polymerase Chain Reaction-Confirmed Mycobacterium ulcerans Infection.” Clin. Infect. Dis. 59 (2014): 1256-1264. PubMed: 25048846.
  4. Degnonvi, H., et al. “Effect of Well Drilling on Buruli Ulcer Incidence in Benin: A Case-Control, Quantitative Survey.” Lancet Planet Health 3 (2019): e349-e356. PubMed: 31439316.

Image:  Mycobacterium ulcerans, strain S4018 (NR-51701) on Lowenstein-Jensen agar (BEI Resources)


EDIII Protein from Powassan Virus
Highlights

Powassan virus (POWV), first described after isolation in1958 from the brain of a fatal case of encephalitis in Powassan, Ontario, Canada, is a reemerging severe neuroinvasive tick-borne disease causing human encephalitis in the United States, Canada and Russia, and the only recognized tick-borne flavivirus endemic to North America.1,2 Though rare, infection by POWV in the United States has recently increased, with over 30 cases reported in 2017, and has a fatality rate of approximately 10%, with long-term neurological sequelae resulting in an estimated 50% of survivors.3,4

The POWV Envelope (E) structural protein is a highly conserved structure comprising the majority of the virus surface with multiple roles in infection, including host cell receptor recognition and binding, and is divided into three domains: Domain I (DI) consisting of a central beta-barrel domain; Domain II (DII) important for dimerization and virion assembly; and Domain III (DIII) characterized by an immunoglobulin-like segment.4 Studies demonstrated that the flavivirus E protein DIII (EDIII) is a primary antigenic target of specific neutralizing antibodies.5

The EDIII protein from the 1958 lineage 1 isolate, Powassan virus, strain LB (BEI Resources NR-51181) is currently in production and coming soon to the BEI Resources catalog as NR-52391, and represents the first commercially available standard for studying such emerging tick-borne infections. NR-52391 is a recombinant form of the truncated EDIII protein containing a C-terminal hexa-histidine tag, produced in a Pichia pastoris expression system and purified by immobilized-metal affinity chromatography. The mature native full-length POWV E protein is 497 residues (GenBank: NP_775516.1).

BEI Resources No.       Product Description
NR-52391 Envelope Domain III (EDIII) Protein from Powassan Virus with C-Termina lHistidine Tag, Strain LB, Recombinant in Yeast – Coming Soon

 

References:

  1. Hermance, M. E. and S. Thangamani. “Powassan Virus: An Emerging Arbovirus of Public Health Concern in North America.” Vector Borne Zoonotic Dis. 17 (2017): 453-462. PubMed: 28498740.
  2. McLean, D. M. and W. L. Donohue. “Powassan Virus: Isolation of Virus from a Fatal Case of Encephalitis.” Can. Med. Assoc. J. 80 (1959): 708-711. PubMed: 13652010.
  3. Kemenesi, G. and K. Bányai. "Tick-Borne Flaviviruses, with a Focus on Powassan Virus." Clin. Microbiol. Rev. 32 (2018): e00106-17. PubMed: 30541872.
  4. “Powassan Virus Statistics & Maps.” Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, https://www.cdc.gov/powassan/statistics.html. Accessed 07 August 2020.
  5. Heinz, F. X. and K. Stiasny. “Flaviviruses and Their Antigenic Structure.” J. Clin. Virol. 55 (2012): 289-295. PubMed: 22999801.

Image:  The dorsal view of a female I. pacificus hard tick (CDC/James Gathany)


Expanded Catalog of Borrelia Species
Highlights

Incidence of tick-borne disease in the United States doubled between 2004 and 2016, and continues to rise inthe United States and in many geographic regions around the world.1,2 Novel methods are needed to improve diagnostic assays and species-level identification, advance surveillance and epidemiological efforts and facilitate drug development of these neglected human pathogens.

The most common bacterial pathogens transmitted by ticks belong to the genus Borrelia and are the causative agents of Lyme borreliosis (Lyme disease) and relapsing fever. Borrelia spp. can be divided into two major groups affecting human health: Borrelia burgdorferi sensu lato complex containing the agents of Lyme borreliosis and Borrelia species associated with human relapsing fever.

Tick-borne relapsing fever (TBRF) occurs worldwide, often in periodic outbreaks, with specific geographic distribution in North America, Europe, Africa and Asia. While most TBRF is transmitted by soft ticks of the Argasidae family, certain species like Borrelia miyamotoi are found in hard Ixodes ticks.3 Louse-borne relapsing fever (LBRF), caused by Borrelia recurrentis, is mainly limited to endemic areas within the Horn of Africa.4 Introduction of LBRF intoindustrialized countries via migration underscores the importance of having effective surveillance, diagnostic and treatment tools available.5

The availability of different Borrelia species to researchers supports development of necessary tools to minimize the effects of the increasing incidence of tick-borne diseases. Recent additions to the BEI Resources catalog include four species of Borrelia from Dr. Gabriele Margos and Dr. Volker Fingerle of the German National Reference Center for Borrelia (NRZ). This deposit includes four species new to the BEI Resources catalog: Borrelia afzelli, Borrelia hispanica, Borrelia miyamotoi and three Borrelia recurrentis (LBRF) strains.

In vitro adaption and growth of Borrelia spirochetes can be challenging. Optimized growth conditions are detailed on the BEI Resources product information sheet for each isolate and customers are encouraged to follow these growth recommendations to ensure success of the culture and recovery from the freezing process.

BEI Resources No.       Product Description
NR-51672 Borrelia recurrentis, Strain PBek5
NR-51673 Borrelia recurrentis, Strain PAbN5
NR-51674 Borrelia recurrentis, Strain PAbJ5
NR-51675 Borrelia miyamotoi, Strain HT316
NR-51676 Borrelia afzelii, Strain PKo7
NR-51677 Borrelia hispanica

 

References:

  1. Rosenberg, R., et al. “Vital Signs: Trends in Reported Vectorborne Disease Cases – United States and Territories, 2004-2016.” MMWR Morb. Mortal. Wkly. Rep. 67 (2018): 496-501. PubMed: 29723166.
  2. Chikeka, I. and J. S. Dumler. “Neglected Bacterial Zoonoses.” Clin. Microbiol. Infect. 21 (2015): 404-415. PubMed: 25964152.
  3. Talagrand-Reboul, E., et al. “Relapsing Fevers: Neglected Tick-Borne Diseases.” Front. Cell. Infect. Microbiol. 8 (2018): 98. PubMed: 29670860.
  4. Warrell, D. A. “Louse-Borne Relapsing Fever (Borrelia recurrentis Infection).” Epidemiol. Infect. 147 (2019): e106. PubMed: 30869050.
  5. Marosevic, D., et al. “First Insights in the Variability of Borrelia recurrentis Genomes.” PLoS Negl. Trop. Dis. 11 (2017): e0005865. PubMed: 28902847.
  6. Fukunaga, M., et al. “Genetic and Phenotypic Analysis of Borrelia miyamotoi sp. nov., Isolated from the Ixodid Tick Ixodes persulcatus, the Vector of Lyme Disease in Japan.” Int. J. Syst. Bacteriol. 45 (1995): 804-810. PubMed: 7547303.
  7. Glöckner, G., et al. “Comparative Genome Analysis: Selection Pressure on the Borrelia VLS Cassettes is Essential for Infectivity.” BMC Genomics 7 (2006): 211. PubMed: 16914037.

Image:  Fluorescence microscopy of Borrelia hispanica, NR-51677 (BEI Resources)


New Tools for Apicomplexan Parasite Research
Highlights

Apicomplexan parasites cause significant morbidity and mortality to humans and livestock animals, and share characteristic morphological features, cytoskeletal components, and mechanisms of replication, motility and invasion. Understanding these mechanisms of infection and pathogenesis requires novel tools that support and further research.

Recently described methods of conditional gene deletion in the apicomplexan parasites Toxoplasma gondii and Plasmodium falciparum, the agents of toxoplasmosis and malaria, respectively, enable reliable gene function and virulence research using the dimerizable Cre (DiCre) strategy.1,2,3 BEI Resources now houses Toxoplasma gondii, strain RHΔku80::DiCre:T2A:CAT (NR-51627) and Plasmodium falciparum, strain NF54::DiCre (MRA-1314; Coming Soon), stable cell lines that express rapamycin-inducible Cre recombinase, thus allowing the conditional deletion of essential and non-essential parasite genes at different life cycle stages.3 These strains offer new opportunities to study genes impacting growth or stage conversion with applications in drug development and vaccination strategies.

Additional tools available from the BEI Resources catalog to support apicomplexan research include molecular standards for the development of quantitative PCR (qPCR) assays against babesiosis, an emergent tickborne parasitic disease that can also be transmitted by blood transfusion. These standards harbor the internal transcribed spacer (ITS) 1, 5.8S ribosomal RNAgene, ITS 2 regions from Babesia microti, strain GI (NR-50741) and Babesia duncani, strain WA1 (NR-50742), the most prevalent agents of babesiosis in the United States. As qPCR assays have become more commonplace in the diagnosis of parasitic infections, these standards are useful in the execution of highly specific and sensitive blood tests using droplet digital or real time PCR technologies.4

BEI Resources No.       Product Description
NR-50741 Plasmid pUC19 Containing the ITS 1, 5.8S rRNA Gene, ITS 2 Region from Babesia microti, Strain GI
NR-50742 Plasmid pUC19 Containing the ITS 1, 5.8S rRNA Gene, ITS 2 Region from Babesia duncani, Strain WA1
NR-51627 Toxoplasma gondii, strain RHΔku80::DiCre:T2A:CAT
MRA-1314 Plasmodium falciparum, strain NF54::DiCre – Coming Soon

 

References:

  1. Hunt, A., et al. “Differential Requirements for Cyclase-Associated Protein (CAP) in Actin-Dependent Processes of Toxoplasma gondii.” ELife 8 (2019): e50598. PubMed: 31577230.
  2. Tibúrcio, M., et al. “A Novel Tool for the Generation of Conditional Knockouts to Study Gene Function across the Plasmodium falciparim Life Cycle.” mBio 10 (2019): e01170-19. PubMed: 31530668.
  3. Jullien, N., et al. “Conditional Transgenesis Using Dimerizable Cre (DiCre).” PLoS One 2 (2007): e1355. PubMed: 18159238.
  4. Wilson, M. et al. “Development of Droplet Digital PCR for the Detection of Babesia microti and Babesia duncani.” Exp. Parasitol. 149 (2015): 24-31. PubMed: 25500215.

Image:  Fluorescence microscopy of Toxoplasma gondii (PLoS Open-Access/Ke Hu and John M. Murray)


Azole-Resistant and Dual-Fluorescent Strains of Candida spp.
Highlights

C. albicans and C. glabrata are ubiquitous in the environment and commensal inhabitants of the normal flora of the oral cavity, gastrointestinal tract and skin of most healthy humans.1,2 For the immunocompromised, however, C. albicans and C. glabrata are the two most commonly recovered pathogenic yeasts in the United States and together are responsible for approximately 70% of all cases of systemic candidiasis, with increasing occurrences of multidrug resistance.1-4

BEI Resources houses over 50 strains of Candida spp. to support candidiasis research. Recent additions to our catalog include an azole-susceptible strain of C. glabrata (NR-51685) and an azole-resistant C. glabrata strain isolated from the same patient after 50-day azole therapy (NR-51686).4 Also newly available is a transgenic strain of C. albicans (NR-51634) that constitutively expresses green fluorescent protein (GFP) and red fluorescent protein via mCherry, which has been used as an in vitro system for fluorescent sorting of C. albicans with macrophages.1

For more information about these and other Candida strains available from BEI Resources, or to contribute to our expanding catalog of biomaterials for fungal research, please contact us at Contact@BEIResources.org.

BEI Resources No. Product Description
NR-51685 Candida glabrata, Strain DSY562 - Azole-Susceptible
NR-51686 Candida glabrata, Strain DSY565 - Azole-Resistant
NR-51634 Candida albicans, Strain CAI4-F2-Neut5L-NAT1-mCherry-GFP

 

References:

  1. Muñoz, J. F., et al. “Coordinated Host-Pathogen Transcriptional Dynamics Revealed Using Sorted Subpopulations and Single Macrophages Infected with Candida albicans.” Nat. Commun. 10 (2019): 1607. PubMed: 30962448.
  2. Brunke, S. and B. Hube. “Two Unlike Cousins: Candida albicans and C. glabrata Infection Strategies.” Cell. Microbiol. 15 (2013): 701-708. PubMed: 23253282.
  3. Hendrickson, J. A., et al. “Antifungal Resistance: A Concerning Trend for the Present and Future.” Curr. Infect. Dis. Rep. 21 (2019): 47. PubMed: 31734730.
  4. Vale-Silva, L., et al. “Comparative Genomics of Two Sequential Candida glabrata Clinical Isolates.” G3 (Bethesda) 7 (2017): 2413-2426. PubMed: 28663342.

Image:  Fluorescence microscopy of transgenic Candida albicans, NR-51634 (BEI Resources)


Pseudomonas aeruginosa Panel for Antibiotic Resistance Research
Highlights

Infections with multidrug-resistant Pseudomonas aeruginosa, one of the most common healthcare-associated infections among immunocompromised and post-surgery patients, affected an estimated 32,600 patients in the United States in 2017, resulting in nearly 3,000 deaths, and is the predominant pathogen causing lung infections in individuals with cystic fibrosis and other pulmonary disorders.1-3 Rising rates of multidrug-resistant isolates of P. aeruginosa limit treatment options, strengthening the need for new antimicrobials and alternative tools. A new collection of P. aeruginosa strains, selected from a respository of over 3,400 clinical isolates collected worldwide between 2003 and 2017, is now available to the research community focusing on multidrug-resistant P. aeruginosa.

This unique panel of 100 highly diverse, multidrug-resistant P. aeruginosa strains from the Multidrug Resistant Organism Repository and Surveillance Network (MRSN) within Walter Reed Army Institute of Research's Bacterial Diseases Branch represents isolates from each phylogenetic group with a wide-range of well-characterized antibiotic resistance patterns. Extensive data is available for each isolate, including isolation history, whole genome sequencing, characterization by mutilocus sequence typing, a comprehensive list of antibiotic resistance genes carried, and antibiotic susceptibilities to eleven clinically relevant antibiotics commonly used to treat P. aeruginosa infections: amikacin, aztreonam, ceftazidime, ciprofloxacin, cefepime, gentamicin, imipenem, levofloxacin, meropenem, tobramycin and piperacillin/tazobactam.

The P. aeruginosa MRSN Diversity Panel is available as both a complete kit containing all 100 strains as BEI Resources NR-51829, as well as individually.

 

References:

  1. “Multidrug-resistant Pseudomonas aeruginosa.” Centers for Disease Control and Prevention, U. S. Department of Health and Human Services, https://www.cdc.gov/drugresistance/pdf/threats-report/pseudomonas-aeruginosa-508.pdf.
  2. Cabot, G., et al. “Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.” Antimicrob. Agents Chemother. 60 (2016): 1767-1778. PubMed: 26729493.
  3. Pang, Z., et al. “Antibiotic Resistance in Pseudomonas aeruginosa: Mechanisms and Alternative Therapeutic Strategies.” Biotechnol. Adv. 37 (2019): 177-192. PubMed: 30500353.

Image:  Illustration of multidrug-resistant Pseudomonas aeruginosa (CDC/Medical Illustrator: Jennifer Oosthuizen)



Information Regarding SARS-CoV-2 Strains and Reagents

FAQs 

Materials Available

Coming Soon

Forms
 

BEI Resources is prioritizing and fast tracking all SARS-CoV-2 registrations and orders.  We anticipate a 12-72 hour turn-around time for all SARS-CoV-2 related registrations and a 24-48 hour turn-around time on approved orders.  Please indicate SARS-CoV-2 in your scope of use in your registration paperwork.  Please contact BEI Resources at contact@beiresources.org for questions.

BEI Resources is working to accession strains of the 2019 novel coronavirus, recently named SARS-CoV-2, identified as the causative agent of the COVID-19 pandemic. We understand how important it is to share virus strains and derivatives with researchers; please contact us if you have suggestions for expanding our catalog offerings.

BEI Resources is currently in process of accessioning variants identified in Japan (NR-54981, SARS-CoV-2, hCoV-19/Japan/TY7-501/2021 and NR-54982, SARS-CoV-2, hCoV-19/Japan/TY7-503/2021) and from the US (Minnesota). Please click on the links above for more information on each isolate.

  

Currently Available SARS-CoV-2 Materials

*Please see the Appendix section in the COA for each virus lot on variant analysis on the specific virus stock
 BEI
 Number  
 Description  Lineage  GISAID
 Clade
 GISAID ID  Clinical Information Available  Registration    AA Substitutions
 per GISAID*
 Virus  
NR-54011 SARS-CoV-2 Isolate hCoV-19/USA/CA_CDC_5574/2020 B.1.1.7 GR  EPI_ISL_751801  Isolated from a nasopharyngeal swab collected on December 29, 2020 in San Diego County, California, USA  BEI Level 3 Link to Mutations
NR-54009 SARS-CoV-2 Isolate hCoV-19/South Africa/KRISP-K005325/2020 B.1.351 GH  EPI_ISL_678615  Isolated from an oropharyngeal swab from a 40-year-old human male in Ugu district, KwaZulu-Natal, South Africa on November 16, 2020  BEI Level 3 Link to Mutations
NR-54008 SARS-CoV-2 hCoV-19/South Africa/KRISP-EC-K005321/2020 B.1.351 GH  EPI_ISL_678570  Isolated from an oropharyngeal swab from a 57-year-old human male in Harry Gwala district, KwaZulu-Natal, South Africa on November 15, 2020  BEI Level 3 Link to Mutations
NR-54000 SARS-CoV-2 hCoV-19/England/204820464/2020 B.1.1.7 GR  EPI_ISL_683466  Isolated from a 58-year-old human male on November 24, 2020 in England, United Kingdom.  BEI Level 3 Link to Mutations
NR-53953 SARS-CoV-2, Isolate hCoV-19/Denmark/DCGC-3024/2020 (also referred to as SARS-CoV-2/hu/DK/CL-5/1) B.1.1.298 GR  EPI_ISL_616802  Isolated from a human who was exposed to a COVID-19 infected European mink (Mustela lutreola) in Northern Jutland, Denmark on October 5, 2020.  BEI Level 3 Link to Mutations
NR-53945 SARS-CoV-2, Isolate hCoV-19/Scotland/CVR2224/2020 B.1.222 G  EPI_ISL_448167  Isolated from a throat swab from a human patient diagnosed with COVID-19, on July 17, 2020 in Scotland, United Kingdom  BEI Level 3 Link to Mutations
NR-53944 SARS-CoV-2, Isolate hCoV-19/Scotland/CVR837/2020 B.1.5 G  EPI_ISL_461705  Isolated from a throat swab from a human patient diagnosed with COVID-19, on July 17, 2020 in Scotland, United Kingdom  BEI Level 3 Link to Mutations
NR-52281 SARS-CoV-2, Isolate USA-WA1/2020 A S  EPI_ISL_404895  Male in 30s, returning traveler from Wuhan. Mild disease; recovered.  BEI Level 3  
NR-52282 SARS-CoV-2, Isolate Hong Kong/VM20001061/2020 A S  EPI_ISL_412028  Isolated from a nasopharyngeal aspirate and throat swab from an adult male patient on January 22, 2020 in Hong Kong  BEI Level 3  
NR-52284 SARS-CoV-2, Isolate Italy-INMI1 None O  EPI_ISL_406959   (fragment) Isolated from sputum of a patient with a respiratory illness who had recently returned from travel to the affected region of China and developed clinical disease (COVID-19) in January 2020 in Rome, Italy.  BEI Level 3  
NR-52359 SARS-CoV-2, Isolate England/02/2020 A S  EPI_ISL_407073  39 yr old Male;  Isolated from Nasopharyngeal aspirate & Throat swab  BEI Level 3  
NR-52368 SARS-CoV-2, Isolate New York 1-PV08001/2020 B.4 O  EPI_ISL_414476 39 yr old Female;  history of travel to Iran  BEI Level 3  
NR-52369 SARS-CoV-2, Isolate Singapore/2/2020 B L  EPI_ISL_407987 Isolated from a throat swab.  Patient has respiratory illness, fever and cough  BEI Level 3  
NR-52370 SARS-CoV-2, Isolate Germany/BavPat1/2020 B G  EPI_ISL_406862 Isolated from Nasopharyngea swab. Typical symptoms of mild upper respiratory tract disease (D614G mutation)  BEI Level 3  
NR-52381 SARS-CoV-2, Isolate USA-IL1/2020 B O  EPI_ISL_404253 63 yr old Female; Isolated from sputum  BEI Level 3  
NR-52382 SARS-CoV-2, Isolate USA-CA1/2020 A S  EPI_ISL_406034 38 yr old Male; Isolated from nasopharyngeal swab  BEI Level 3  
NR-52383 SARS-CoV-2, Isolate USA-AZ1/2020 A S  EPI_ISL_406223 26 yr old Male; Isolated from bucal swab  BEI Level 3  
NR-52384 SARS-CoV-2, Isolate USA-WI1/2020 B L  EPI_ISL_408670 52 yr old Female; Isolated from nasopharyngeal swab  BEI Level 3  
NR-52385 SARS-CoV-2, Isolate USA-CA3/2020 B L  EPI_ISL_408008 72 yr old Female; Isolated from oropharyngeal swab  BEI Level 3  
NR-52386 SARS-CoV-2, Isolate USA-CA4/2020 B L  EPI_ISL_408009 57 yr old Male; Isolated from nasopharyngeal swab  BEI Level 3  
NR-52387 SARS-CoV-2, Isolate USA-CA2/2020 B.2 O  EPI_ISL_406036 54 yr old Male; Isolated from nasopharyngeal swab  BEI Level 3  
NR-52439 SARS-CoV-2, Isolate Chile/Santiago_op4d1/2020 A.2 S  EPI_ISL_415661 Isolated from a Nasal Swab.  Patient has respiratory tract infection. History of travel to Europe  BEI Level 3  
NR-53514 SARS-CoV-2, Isolate New York-PV08410/2020 B.1 GH  EPI_ISL_421374 63 yr old Male; severe COVID19 with fatal outcome  BEI Level 3  
NR-53515 SARS-CoV-2, Isolate New York-PV08449/2020 B.1 GH  EPI_ISL_421400 88 yr old Female; severe COVID19 with fatal outcome  BEI Level 3  
NR-53516 SARS-CoV-2, Isolate New York-PV09158/2020 B.1.3 GH  EPI_ISL_422525 62 yr old Male; severe COVID19 with fatal outcome  BEI Level 3  
NR-53517 SARS-CoV-2, Isolate New York-PV09197/2020 B.1.3 GH  EPI_ISL_422552 90 yr old Male; severe COVID19 with fatal outcome  BEI Level 3  
NR-53565 SARS-CoV-2, Isolate Canada/ON/VIDO-01/2020 B L  EPI_ISL_425177 Isolated from a human patient sample collected on January 23, 2020 in Ontario, Canada  BEI Level 3  
NR-52390 Adenovirus Serotype 5, Clone Ad5-CMV-hACE2/RSV-eGFP, Recombinant Expressing Human ACE2  BEI Level 2  
 Nucleic Acid  
NR-52285 Genomic RNA from SARS-CoV-2, Isolate USA-WA1/2020  BEI Level 2  
NR-52388 Genomic RNA from SARS-CoV-2, Isolate Hong Kong/VM20001061/2020  BEI Level 2  
NR-52498 Genomic RNA from SARS-CoV-2, Isolate Italy-INMI1   BEI Level 2  
NR-52499 Genomic RNA from SARS-CoV-2, Isolate England/02/2020   BEI Level 2  
NR-52501 Genomic RNA from SARS-CoV-2, Isolate Singapore/2/2020   BEI Level 2  
NR-52502 Genomic RNA from SARS-CoV-2, Isolate Germany/BavPat1/2020   BEI Level 2  
NR-52503 Genomic RNA from SARS-CoV-2, Isolate USA-IL1/2020   BEI Level 2  
NR-52504 Genomic RNA from SARS-CoV-2, Isolate USA-CA1/2020   BEI Level 2  
NR-52505 Genomic RNA from SARS-CoV-2, Isolate USA-AZ1/2020   BEI Level 2  
NR-52506 Genomic RNA from SARS-CoV-2, Isolate USA-WI1/2020   BEI Level 2  
NR-52507 Genomic RNA from SARS-CoV-2, Isolate USA-CA3/2020   BEI Level 2  
NR-52508 Genomic RNA from SARS-CoV-2, Isolate USA-CA4/2020   BEI Level 2  
NR-52509 Genomic RNA from SARS-CoV-2, Isolate USA-CA2/2020   BEI Level 2  
NR-52510 Genomic RNA from SARS-CoV-2, Isolate Chile/Santiago_op4d1/2020   BEI Level 2  
NR-53518 Genomic RNA from SARS-CoV-2, Isolate New York-PV08410/2020   BEI Level 2  
NR-52346 Quantitative PCR (qPCR) Control RNA from Inactivated SARS Coronavirus, Urbani  BEI Level 1  
NR-52347 Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020  BEI Level 1  
 Inactivated Organisms  
NR-52286 SARS-CoV-2, Isolate USA-WA1/2020, Heat Inactivated   BEI Level 1  
NR-52287 SARS-CoV-2, Isolate USA-WA1/2020, Gamma-Irradiated   BEI Level 1  
NR-52349 Quantitative PCR (qPCR) Extraction Control from Inactivated SARS Coronavirus, Urbani   BEI Level 1  
NR-52350 Quantitative PCR (qPCR) Extraction Control from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020   BEI Level 1  
 Cell Line  
NR-52511 Human Embryonic Kidney Cells (HEK-293T) Expressing Human Angiotensin-Converting Enzyme 2, HEK-293T-hACE2 Cell Line   BEI Level 2  
NR-53258 Vero E6 Cell Lysate Control, Gamma-Irradiated (To be used with NR-52287)    BEI Level 1  
NR-53522 Human Lung Carcinoma Cells (A549) Expressing Human Angiotensin-Converting Enzyme 2 (HA-FLAG)   BEI Level 1  
NR-53726 African Green Monkey Kidney Epithelial Cells (Vero E6) Expressing High Endogenous Angiotensin-Converting Enzyme 2   BEI Level 2  
NR-53821 Human Lung Carcinoma Cells (A549) Expressing Human Angiotensin-Converting Enzyme 2   BEI Level 1  
 Monoclonal Antibody  
NR-52481 Monoclonal Anti-SARS Coronavirus Recombinant Human Antibody, Clone CR3022 (produced in HEK293 Cells)   BEI Level 1  
NR-53787 Monoclonal Anti-SARS Coronavirus Spike Glycoprotein S1 Domain (produced in vitro)   BEI Level 1  
NR-53788 Monoclonal Anti-SARS-CoV-2 Spike Glycoprotein S1 Domain (produced in vitro)   BEI Level 1  
NR-53789 Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Spike Glycoprotein Receptor Binding Domain (RBD), Chimeric Antibody (produced in vitro)   BEI Level 1  
NR-53790 Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Spike Glycoprotein Receptor Binding Domain (RBD), Chimeric Antibody (produced in vitro)   BEI Level 1  
NR-53791 Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Nucleocapsid Protein, rabbit MAb (produced in vitro)   BEI Level 1  
NR-53792 Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Nucleocapsid Protein, mouse MAb (produced in vitro)  BEI Level 1  
NR-53793 Monoclonal Anti-SARS-CoV-2 Nucleocapsid Protein (produced in vitro)  BEI Level 1  
NR-53794 Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Nucleocapsid Protein (produced in vitro)  BEI Level 1  
NR-53795 Monoclonal Anti-SARS-CoV-2 Spike Glycoprotein RBD-mFc Fusion Protein (produced in vitro)  BEI Level 1  
NR-53796 Monoclonal Anti-SARS-CoV-2 Spike RBD-mFc Fusion Protein (produced in vitro)  BEI Level 1  
NR-53876 Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana)  BEI Level 1  
 Serum/Plasma  
NR-52401 Pooled Non-Human Primate Convalescent Serum to SARS-CoV-2, Gamma-Irradiated   BEI Level 2  
NR-52947 Polyclonal Anti-SARS-CoV-2 Spike Glycoprotein (IgG, Rabbit)   BEI Level 1  
 Protein  
NR-52307 Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus  BEI Level 1  
NR-52308 Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus (This item replaces NR-52396)   BEI Level 1  
NR-52366 Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293 Cells (This item replaces NR-52306)  BEI Level 1  
NR-52397 Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293F Cells  BEI Level 1  
NR-52724 Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from HEK293 Cells 
(related product for NR-53257)  
 BEI Level 1  
NR-52946 Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293T Cells  BEI Level 1  
NR-53246 Nucleocapsid Protein N-Terminal RNA Binding Domain from SARS-CoV-2, Wuhan-Hu-1 with N-Terminal Histidine Tag, Recombinant from E. coli  BEI Level 1  
NR-53524 Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine and Avi Tags, Recombinant from HEK293F Cells   BEI Level 1  
NR-53589 Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from HEK293 Cells   BEI Level 1  
NR-53769 Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 HexaPro with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from CHO Cells   BEI Level 1  
NR-53797 Nucleocapsid Protein from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus   BEI Level 1  
NR-53798 Spike Glycoprotein S1 Domain from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293 Cells   BEI Level 1  
NR-53799 Spike Glycoprotein S2 Extracellular Domain (ECD) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus   BEI Level 1  
NR-53800 Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293 Cells   BEI Level 1  
NR-53937 Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from CHO Cells   BEI Level 1  
NR-54004 Spike Glycoprotein RBD from SARS-CoV-2, United Kingdom Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells   BEI Level 1  
NR-54005 Spike Glycoprotein RBD from SARS-CoV-2, South Africa Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells   BEI Level 1  
 Peptide Array  
NR-52403 Peptide Array, SARS-CoV-2 Membrane (M) Protein   BEI Level 1  
NR-52405 Peptide Array, SARS-CoV-2 Envelope (E) Protein   BEI Level 1  
NR-52418 Peptide Array, SARS Coronavirus Spike (S) Protein   BEI Level 1  
NR-52419 Peptide Array, SARS Coronavirus Nucleocapsid (N) Protein   BEI Level 1  
 Plasmid  
NR-53816 SARS-CoV-2, Wuhan-Hu-1 Spike-Pseudotyped Lentiviral Kit V2    BEI Level 1  
NR-53817 SARS-CoV-2, Wuhan-Hu-1 Spike D614G-Pseudotyped Lentiviral Kit    BEI Level 1  
NR-53742 Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene with C-Terminal Deletion    BEI Level 1  
NR-53765 Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene, D614G Mutant with C-Terminal Deletion    BEI Level 1  
NR-53260 Plasmid Set for Anti-SARS Coronavirus Human Monoclonal Antibody CR3022    BEI Level 1  
NR-52309 Vector pCAGGS Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene RBD with C-Terminal Hexa-Histidine Tag   BEI Level 1  
NR-52310 Vector pCAGGS Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene   BEI Level 1  
NR-52394 Vector pCAGGS Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene (soluble, stabilized)  BEI Level 1  
NR-52420 Vector pcDNA3.1(-) Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene   BEI Level 1  
NR-52421 Vector pCMV Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain   BEI Level 1  
NR-52422 Vector pcDNA3.1(-) Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein RBD   BEI Level 1  
NR-52423 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 SARS-CoV Unique Domain Gene   BEI Level 1  
NR-52424 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 9 Gene    BEI Level 1  
NR-52425 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 10 Gene   BEI Level 1  
NR-52426 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 15 Gene   BEI Level 1  
NR-52427 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 16 Gene   BEI Level 1  
NR-52428 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein N-Terminal Domain   BEI Level 1  
NR-52429 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Nucleocapsid Protein RNA Binding Domain Gene   BEI Level 1  
NR-52430 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein RBD   BEI Level 1  
NR-52431 Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene   BEI Level 1  
NR-52432 Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 7 Gene   BEI Level 1  
NR-52433 Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 14 Gene   BEI Level 1  
NR-52434 Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Nucleocapsid Protein C-Terminal Domain Gene   BEI Level 1  
NR-52435 Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 4 Gene, Cytoplasmic C-Terminal Domain   BEI Level 1  
NR-52512 Vector pHAGE2 Containing the Angiotensin-Converting Enzyme 2 Gene   BEI Level 1  
NR-52513 Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain Mutant, HA Tag   BEI Level 1  
NR-52514 Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein   BEI Level 1  
NR-52515 Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain Mutant ALAYT   BEI Level 1  
NR-52520 Vector pHAGE2 Containing the ZsGreen Gene   BEI Level 1  
NR-52563 Modified pαH Vector Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain   BEI Level 1  
NR-52564 Modified pαH Vector Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein   BEI Level 1  
NR-52565 Modified pαH Vector Containing the Human Angiotensin-Converting Enzyme 2   BEI Level 1  
NR-52897 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Papain-Like Protease Gene   BEI Level 1  
NR-52898 Vector pCSGID Containing the SARS-CoV-2, Wuhan-Hu-1 3C-Like Protease Gene   BEI Level 1  
NR-52899 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 1 Gene   BEI Level 1  
NR-52900 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 7 Gene   BEI Level 1  
NR-52901 Vector pMCSG120 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene   BEI Level 1  
NR-52902 Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene   BEI Level 1  
NR-52949 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 1 Gene   BEI Level 1  
NR-52950 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 2 Gene   BEI Level 1  
NR-52951 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 4 Gene   BEI Level 1  
NR-52953 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 3C-Like Protease Gene, C145A Mutant   BEI Level 1  
NR-52955 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 7 Gene   BEI Level 1  
NR-52956 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 8 Gene   BEI Level 1  
NR-52957 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 9 Gene   BEI Level 1  
NR-52958 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 10 Gene   BEI Level 1  
NR-52959 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 11 Gene   BEI Level 1  
NR-52960 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 12 Gene   BEI Level 1  
NR-52961 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 13 Gene   BEI Level 1  
NR-52962 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA WA1/2020 Non-Structural Protein 14 Gene   BEI Level 1  
NR-52963 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 15 Gene   BEI Level 1  
NR-52965 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 3a Gene   BEI Level 1  
NR-52966 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 3b Gene   BEI Level 1  
NR-52967 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Envelope Gene   BEI Level 1  
NR-52968 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Membrane Glycoprotein Gene   BEI Level 1  
NR-52969 Vector pLVX-EF1a-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 6 Gene   BEI Level 1  
NR-52970 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 7a Gene   BEI Level 1  
NR-52971 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 7b Gene  BEI Level 1  
NR-52972 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 8 Gene  BEI Level 1  
NR-52973 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Nucleocapsid Gene   BEI Level 1  
NR-52974 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 9b Gene  BEI Level 1  
NR-52975 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 9c Gene  BEI Level 1  
NR-52976 Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 10 Gene   BEI Level 1  
NR-52977 Vector pLVX-EF1α-IRES-Puro Containing the Enhanced Green Fluorescent Protein   BEI Level 1  
NR-53496 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 1 Gene   BEI Level 1  
NR-53497 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 4 Gene   BEI Level 1  
NR-53498 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 6 Gene   BEI Level 1  
NR-53499 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 7 Gene   BEI Level 1  
NR-53500 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene   BEI Level 1  
NR-53501 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 9 Gene   BEI Level 1  
NR-53502 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 10 Gene    BEI Level 1  
NR-53503 Vector pFastbac1 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 12 Gene    BEI Level 1  
NR-53504 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 13 Gene    BEI Level 1  
NR-53505 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 14 Gene    BEI Level 1  
NR-53506 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 15 Gene    BEI Level 1  
NR-53507 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Nucleocapsid Gene    BEI Level 1  
NR-53508 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Membrane Glycoprotein Gene    BEI Level 1  
NR-53509 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Open Reading Frame 3a Gene    BEI Level 1  
NR-53510 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Open Reading Frame 7a Gene    BEI Level 1  
NR-53511 Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 16 Gene    BEI Level 1  
NR-53587 Modified pαH Vector Containing the SARS-CoV-2, Wuhan-Hu-1 HexaPro Spike Glycoprotein Ectodomain    BEI Level 1  
NR-53696 Vector pCMV/R Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene    BEI Level 1  

 

We anticipate a large number of requests from the research community for these reagents, and we cannot guarantee how quickly stock will become available. Please continue checking for updates.

If you wish to transfer SARS-CoV-2 materials, please use the guidance provided in the Emergency Use Simple Letter Agreement.

  

Coming Soon and Expected Availability

 Item Number   Description  Expected Availability   AA Substitutions per GISAID* 
 Virus  
 NR-54981  SARS-CoV-2, hCoV-19/Japan/TY7-501/2021   TBD  Link to Mutations
 NR-54982  SARS-CoV-2, hCoV-19/Japan/TY7-503/2021   TBD  Link to Mutations
 NR-54985  SARS-CoV-2, hCoV-19/USA/MD-HP12112/2021  TBD  Link to Mutations
 NR-54986  SARS-CoV-2, hCoV-19/USA/MD-HP12155/2020  TBD  Link to Mutations
 NR-54987  SARS-CoV-2, hCoV-19/USA/MD-HP01101/2021  TBD  Link to Mutations
 Nucleic Acid  
 NR-52389  Genomic RNA from SARS-CoV-2, Isolate New York-PV08001/2020  Early 2021  
 TBD  Genomic RNA from SARS-CoV-2, Isolate hCoV-19/USA/CA_CDC_5574/2020  TBD  
 TBD  Genomic RNA from SARS-CoV-2, hCoV-19/South Africa/KRISP-K005325/2020  TBD  
 Inactivated Organisms  
 TBD  Heat inactivated SARS-CoV-2 Isolate hCoV-19/USA/CA_CDC_5574/2020   TBD  
 TBD  Gamma Irradiated SARS-CoV-2 Isolate hCoV-19/USA/CA_CDC_5574/2020   TBD  
 TBD  Heat Inactivated, SARS-CoV-2, hCoV-19/South Africa/KRISP-K005325/2020   TBD  
 TBD  Gamma Irradiated SARS-CoV-2, hCoV-19/South Africa/KRISP-K005325/2020   TBD  
 Monoclonal Antibody  
 NR-52392  Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana)   Early 2021    
 Protein  
 NR-52348  Spike Glycoprotein from SARS-CoV-2, Wuhan-Hu-1, Recombinant from HEK293T Cells   Early 2021  
 Peptide Array  
 NR-52402  Peptide Array, SARS-CoV-2 Spike (S) Glycoprotein  TBD   
 NR-52404  Peptide Array, SARS-CoV-2 Nucleocapsid (N) Protein  TBD   
 Plasmid  
 NR-52954  Plasmid pLVX-EF1α-IRES-Puro SARS-CoV-2, nsp6 (TST)   Early 2021  
 NR-53762  icSARS-CoV-2-WT, infectious cDNA USA-WA1/2020, plasmid Kit   Early 2021   
 NR-53763  icSARS-CoV-2-eGFP, infectious cDNA USA-WA1/2020, plasmid Kit   Early 2021   
 NR-53764  icSARS-CoV-2-nLuc, infectious cDNA USA-WA1/2020, plasmid Kit   Early 2021   

*Please see the Appendix section in the COA for each virus lot on variant analysis on the specific virus stock

The BEI Resources catalog offers additional coronavirus materials ready and available for distribution to qualified laboratories.

For access to BEI Resources full catalog, click here.

 

Frequently Asked Questions 

  1. Is there currently a shortage or delay in receiving SARS-CoV-2 virus isolates or RNA from BEI Resources?
  2. How long will it take to get SARS-CoV-2 materials?
  3. How long will it take to process my registration to receive SARS-CoV-2 materials?
  4. Who is qualified to receive SARS-CoV-2 materials?
  5. What level of registration do I need to receive SARS-CoV-2 materials?
  6. If I have questions regarding SARS-CoV-2 materials, who do I contact?
  7. How much do SARS-CoV-2 materials cost?
  8. What is the Emergency Use Simple Letter Agreement (EUSLA)?
  9. Which SARS-CoV-2 materials distributed by BEI fall under the EUSLA?
  10. Can I transfer SARS-CoV-2 materials?
  11. Can I commercialize SARS COV-2 materials?
  12. Are COVID-19 patient samples currently available from BEI Resources?
  13. How do I obtain test kits for COVID-19?
  14. Why is the SARS-CoV-2 genomic RNA only distributed to facilities which have BSL-2 laboratories?
  15. Am I required to obtain a CDC permit for the transfer of SARS-CoV-2 isolates?
  16. Where do I find product documentation (Product Sheet, Certificate of Analyses, etc.) for BEI Resources products?
  17. How do I find out about SARS-CoV-2 products coming soon?

 

Question: Is there currently a shortage or delay in receiving SARS-CoV-2 virus isolates or RNA from BEI Resources?

Answer: No, BEI Resources currently does not have a shortage or a delay in shipping virus and RNA to qualified laboratories. We understand how important it is to share virus strains and derivatives with researchers, especially during an outbreak.

Back to Questions

 

Question: How long will it take to get SARS-CoV-2 materials?

Answer: BEI Resources is prioritizing all SARS-CoV-2 shipments.  Shipments are generally being made within 24-48 hours of completed requests.  If permits are required, these timelines are dependent on obtaining those permits.  Please contact us at contact@beiresources.org for any shipment questions.

Back to Questions

 

Question: How long will it take to process my registration to receive SARS-CoV-2 materials?

Answer: BEI Resources is prioritizing and fast tracking all SARS-CoV-2 registrations.  We anticipate a 12-72 hour turn-around time for all SARS-CoV-2 related registrations.  Please indicate SARS-CoV-2 in your scope of use.  Please contact BEI Resources at contact@beiresources.org for questions.

Back to Questions

 

Question: Who is qualified to receive SARS-CoV-2 materials?

Answer: Registration with BEI Resources is required to request SARS-CoV-2 materials. BEI Resources reagents are shared with registered individuals and organizations doing research on Emerging Infections and other relevant areas of interest related to Microbiology. To register you must be affiliated with a public, private, academic, non-profit or for-profit institution. Registrants must demonstrate they work in an established institution with facilities and safety programs appropriate for the Level of registration requested.

Back to Questions

 

Question: What level of registration do I need to receive SARS-CoV-2 materials?

Answer: Each product on the BEI Resources website lists a BEI Resources level of registration.  Interested researchers will need to ensure they are registered at the appropriate level to receive materials.  Please click here for registration instructions.  If you need to upgrade your registration to a higher level, please click here for instructions.

Back to Questions

 

Question: If I have questions regarding SARS-CoV-2 materials, who do I contact?

Answer: Please contact BEI Resources at contact@beiresources.org for any questions regarding SARS-CoV-2 materials.

Back to Questions

 

Question: How much do SARS-CoV-2 materials cost?

Answer: All BEI Resources reagents, including SARS-CoV-2 materials, are provided world-wide at no cost. While there is no cost for the reagents themselves, additional shipping and handling charges may apply and will display in the shopping cart if applicable.

Back to Questions

 

Question: What is the Emergency Use Simple Letter Agreement (EUSLA)?

Answer: The Emergency Use Simple Letter Agreement outlines the terms in which SARS-CoV-2 materials are being provided.  In light of the emergence of the novel coronavirus, 2019-SARS-CoV-2, and urgent need to mitigate the pathogen’s spread, the EUSLA was instituted for the provision of these materials under the terms outlined in the agreement. The EUSLA is not negotiable.

Back to Questions

 

Question: Which SARS-CoV-2 materials distributed by BEI fall under the EUSLA?

Answer: The viruses, nucleic acids, and inactivated SARS-CoV-2 organisms, along with the gamma irradiated NHP convalescent serum from SARS-CoV-2, are distributed under the terms of the EUSLA. Please note that the signature of the biosafety officer to certify that your facility can safely handle the material is required for receipt of the virus. The following is a list of items distributed by BEI under the EUSLA:

 

 Item Number   Description
 NR-52281  SARS-CoV-2, Isolate USA-WA1/2020
 NR-52282  SARS-CoV-2, Isolate Hong Kong/VM20001061/2020
 NR-52284  SARS-CoV-2, Isolate Italy-INMI1
 NR-52359  SARS-CoV-2, Isolate England/02/2020
 NR-52368  SARS-CoV-2, Isolate New York 1-PV08001/2020
 NR-52369  SARS-CoV-2, Isolate Singapore/2/2020
 NR-52370  SARS-CoV-2, Isolate Germany/BavPat1/2020
 NR-52381  SARS-CoV-2, Isolate USA-IL1/2020
 NR-52382  SARS-CoV-2, Isolate USA-CA1/2020
 NR-52383  SARS-CoV-2, Isolate USA-AZ1/2020
 NR-52384  SARS-CoV-2, Isolate USA-WI1/2020
 NR-52385  SARS-CoV-2, Isolate USA-CA3/2020
 NR-52386  SARS-CoV-2, Isolate USA-CA4/2020
 NR-52387  SARS-CoV-2, Isolate USA-CA2/2020
 NR-52439  SARS-CoV-2, Isolate Chile/Santiago_op4d1/2020
 NR-53514  SARS-CoV-2, Isolate New York-PV08410/2020
 NR-53515  SARS-CoV-2, Isolate New York-PV08449/2020
 NR-53516  SARS-CoV-2, Isolate New York-PV09158/2020
 NR-53517  SARS-CoV-2, Isolate New York-PV09197/2020
 NR-53565  SARS-CoV-2, Isolate Canada/ON/VIDO-01/2020
 NR-53944  SARS-CoV-2, Isolate hCoV-19/Scotland/CVR837/2020
 NR-53945  SARS-CoV-2, Isolate hCoV-19/Scotland/CVR2224/2020
 NR-53953  SARS-CoV-2, Isolate hu/DK/CL-5/1
 NR-54000  SARS-CoV-2 hCoV-19/England/204820464/2020
 NR-54008  SARS-CoV-2 hCoV-19/South Africa/KRISP-EC-K005321/2020
 NR-54009  SARS-CoV-2 Isolate hCoV-19/South Africa/KRISP-K005325/2020
 NR-54011  SARS-CoV-2 Isolate hCoV-19/USA/CA_CDC_5574/2020
 NR-52285  Genomic RNA from SARS-CoV-2, Isolate USA-WA1/2020
 NR-52388  Genomic RNA from SARS-CoV-2, Isolate Hong Kong/VM20001061/2020
 NR-52498  Genomic RNA from SARS-CoV-2, Isolate Italy-INMI1
 NR-52499  Genomic RNA from SARS-CoV-2, Isolate England/02/2020
 NR-52501  Genomic RNA from SARS-CoV-2, Isolate Singapore/2/2020
 NR-52502  Genomic RNA from SARS-CoV-2, Isolate Germany/BavPat1/2020
 NR-52503  Genomic RNA from SARS-CoV-2, Isolate USA-IL1/2020
 NR-52504  Genomic RNA from SARS-CoV-2, Isolate USA-CA1/2020
 NR-52505  Genomic RNA from SARS-CoV-2, Isolate USA-AZ1/2020
 NR-52506  Genomic RNA from SARS-CoV-2, Isolate USA-WI1/2020
 NR-52507  Genomic RNA from SARS-CoV-2, Isolate USA-CA3/2020
 NR-52508  Genomic RNA from SARS-CoV-2, Isolate USA-CA4/2020
 NR-52509  Genomic RNA from SARS-CoV-2, Isolate USA-CA2/2020
 NR-52510  Genomic RNA from SARS-CoV-2, Isolate Chile/Santiago_op4d1/2020
 NR-53518  Genomic RNA from SARS-CoV-2, Isolate New York-PV08410/2020 
 NR-52347  Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020
 NR-52286  SARS-CoV-2, Isolate USA-WA1/2020, Heat Inactivated 
 NR-52287  SARS-CoV-2, Isolate USA-WA1/2020, Gamma-Irradiated 
 NR-52350  Quantitative PCR (qPCR) Extraction Control from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020 
 NR-52401  Pooled Non-Human Primate Convalescent Serum to SARS-CoV-2, Gamma-Irradiated 
 NR-53593 - NR-53692   SARS-CoV-2, Human Plasma and PBMC Samples
 NR-53736  SARS-CoV-2, Human Peripheral Blood Mononuclear Cells (PBMC), Subject ID: LPEQAP142
 NR-53737  SARS-CoV-2, Human Plasma, Subject ID: LPEQAP142
 NR-53738  SARS-CoV-2, Human Serum, Subject ID: 0873-294

 

Back to Questions

 

Question: Can I transfer SARS-CoV-2 materials?

Answer: “Material” as used in this answer, means the original material or any unmodified progeny received from BEI Resources. SARS-CoV-2 materials received under the EUSLA may be further distributed to other entities for legitimate purposes required to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of SARS-CoV-2 and under terms no more restrictive than the Emergency Use Simple Letter Agreement (EUSLA). To ensure compliance with this, copies of the EUSLA or MTAs recording all further transfers must be sent back to contact@beiresources.org. This requirement must also be incorporated for further transfers. The recipient and provider agree to transfer, use, manage, and control the SARS-CoV-2 materials in compliance with all applicable laws and regulations. When these commodities, technology or software are exported from the United States, the recipient agrees to comply with the Export Administration Regulations. Diversion contrary to U.S. law is prohibited.

Any products made by you, that are not considered the original material or unmodified progeny, are excluded from this requirement, and you are free to share and commercialize those products as your own products.

Back to Questions

 

Question: Can I commercialize SARS COV-2 materials? 

Answer: “Material” as used in this answer, means the original material or any unmodified progeny received from BEI Resources. SARS-CoV-2 materials received under the EUSLA are made available for any legitimate purpose, including commercial purposes, as long as they are to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of the 2019 SARS-CoV-2. Any transfer of the original material or any unmodified progeny must be done under the terms of the EUSLA (see question above regarding transfer of SARS-CoV-2 materials). Any products made by you, that are not considered the original material or unmodified progeny, are excluded from this requirement, and you are free to share and commercialize those products as your own products.

Back to Questions

 

Question: Are COVID-19 patient samples currently available from BEI Resources?

Answer: We understand how important it is to share patient samples, including sera, nasal swabs and PBMCs, with researchers, especially during an outbreak. We will have a very limited number of samples available. Requestors must limit their orders to 5 samples of serum/plasma. We anticipate a large number of requests from the research community for patient samples related to the pandemic, and will continually work towards making more samples available. Please order according to the limits above and contact our email box at contact@beiresources.org with any questions. If we are not able to fill your needs, please contact us so we can forward your request to NIAID to prioritize those samples once available.

Back to Questions

 

Question: How do I obtain test kits for COVID-19?

Answer: Test kits are not distributed through BEI Resources. The CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel was developed for qualified domestic public health laboratories to detect SARS-CoV-2. The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) on February 4, 2020, to enable emergency use of the test kit in the United States. CDC has produced EUA and Research Use Only (RUO) test kits that are now available to order by domestic and international public health partners through IRR (www.internationalreagentresource.org). Please contact the International Reagent Resources program for more information – contact@internationalreagentresource.org.

Back to Questions

 

Question: Why is the SARS-CoV-2 genomic RNA only distributed to facilities which have BSL-2 laboratories?

Answer: CDC guidelines state that molecular analysis of extracted nucleic acid preparations should be performed in BSL-2 facility using standard BSL-2 work practices. The CDC guidelines can be found in the following link: https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html

Back to Questions

 

Question: Am I required to obtain a CDC permit for the transfer of SARS-CoV-2 isolates? 

Answer: The BEI Resources website provides a link on each product detail page for applicable permits. Please check the individual product detail pages for this information. SARS-CoV-2 isolates which originate from the United States do not require a CDC permit for domestic transfer. SARS-CoV-2 isolates which are deposited into BEI Resources outside of the USA, will be brought into the repository under a CDC permit, and will require a CDC permit for transfer.

Back to Questions 

 

Question: Where do I find product documentation (Product Sheet, Certificate of Analyses, etc.) for BEI Resources products?

Answer: All Product Sheets and Certificates of Analysis can be found on the BEI Resources website. Perform a search for the product, and you will find the documentation. Any product listed as requiring a BSL-3 facility, will require login first to view the documentation. Only BEI Level 3 registrants will have access to view and download products requiring BSL-3 facilities.

Back to Questions 

 

Question: How do I find out about SARS-CoV-2 products coming soon?

Answer: BEI Resources will list the status of SARS-CoV-2 products coming soon in the table above titled Coming Soon and Expected Availability.

Back to Questions 

 

Forms

Emergency Use Simple Letter Agreement (EUSLA)

 

Back to the top


Extensively Drug-Resistant Salmonella typhi H58 Clone
Highlights

Multidrug-resistant (MDR) isolates of S. enterica subsp. enterica serovar Typhi (S. typhi), the causative agent of typhoid fever, prevalent in parts of Asia and Africa are often associated with the dominant H58 haplotype, which harbors an IncHI1 plasmid with multiple resistance genes to first-line drugs, including blaTEM-1 (ampicillin), catA1 (chloramphenicol), dfrA7, sul1, sul2 (sulfamethoxazole/trimethoprim) and strAB (streptomycin) resistance genes.1

The recent emergence of a novel, extensively drug-resistant (XDR) S. typhi H58 clone with additional resistance to fluoroquinolones and third-generation cephalosporins has been reported in Sindh, Pakistan.1,2 This XDR clone encodes a chromosomally located resistance region and harbors the antibiotic resistance-associated IncY plasmid p60006, specific to XDR isolates in this phylogenetic branch.1 This plasmid encodes additional elements, including the extended-spectrum beta-lactamase (blaCTX-M-15) and fluoroquinolone (qnrS) resistance genes, and exhibited high sequence identity to plasmids found in other enteric bacteria, particularly Escherichia coli, isolated from widely distributed geographic locations.1

Five strains of this XDR S. typhi clone from the Pakistan outbreak have been recently added to the BEI Resources catalog, expanding our collection of bacteria with unique resistance profiles to support antimicrobial resistance research:

BEI Resources No. Product Description
NR-51629 Salmonella enterica subsp. enterica (Serovar Typhi), Strain BL6802
NR-51630 Salmonella enterica subsp. enterica (Serovar Typhi), Strain BL53977
NR-51631 Salmonella enterica subsp. enterica (Serovar Typhi), Strain BL55334
NR-51632 Salmonella enterica subsp. enterica (Serovar Typhi), Strain BL55719
NR-51633 Salmonella enterica subsp. enterica (Serovar Typhi), Strain BL0083

 

References:

  1. Klemm, E. J., et al. “Emergence of an Extensively Drug-Resistant Salmonella enterica Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-Generation Cephalosporins.” MBio 9 (2018): e00105-18. PubMed: 29463654.
  2. Chatham-Stephens, K., et al. “Emergence of Extensively Drug-Resistant Salmonella Typhi Infections Among Travelers to or from Pakistan - United States, 2016-2018.” MMWR Morb. Mortal. Wkly. Rep. 68 (2019): 11- 13. PubMed: 30629573.

Image:  Computer-generated image of Salmonella serotype Typhi bacteria (CDC/Medical Illustrator)


Virus Highlight - Usutu Virus
Highlights

Usutu Virus (USUV) is an emerging mosquito-borne flavivirus belonging to the Japanese encephalitis virus serocomplex, with a similar transmission cycle as West Nile virus.2,3 USUV is maintained in the environment through an enzootic cycle between several bird and mosquito species, with humans and mammals as the incidental dead-end hosts.2,3

First isolated in 1959 from Culex neavei mosquitos in South Africa, and named after the nearby Usutu River, USUV has spread from southern Africa to Europe by way of migratory birds, thought to be the major amplifying host, where it has caused significant avian outbreaks and infections in humans and horses.1-3 Infections in humans, while low, range from mild and asymptomatic to serious neuroinvasive diseases like encephalitis and meningoencephalitis. Co-circulation with West Nile virus, confirmed in numerous European countries in mosquito, bird and horse species, and positive serology for both viruses reported in both birds and humans, raises epidemiological issues, furthering the need for research and diagnostic tools to address USUV as a potential human pathogen in the future.2-4

BEI Resources supports this continuing research by offering two Usutu virus isolates available in the BEI Resources catalog: ENT MP 1626 (NR-51185), isolated in 1962 from Mansonia aurites mosquitoes in Zika Forest, Uganda, and the prototype African strain SAAR 1776 (NR-51184), the first isolation of the virus in 1959 from Culex neavei mosquitos in South Africa.

References:

  1. McIntosh, B. M. “Usutu (SAAr 1776); Nouvel Arbovirus du Groupe B.” Int. Cat. Arboviruses 3 (1985): 367- 374.
  2. Clé, M., et al. “Usutu Virus: A New Threat?” Epidemiol. Infect. 147 (2019): e232. PubMed: 31364580.
  3. Roesch, F., et al. “Usutu Virus: An Arbovirus on the Rise.” Viruses 11 (2019): E640. PubMed: 31336826.
  4. Nikolay, B. “A Review of West Nile and Usutu Virus Co-Circulation in Europe: How Much Do Transmission Cycles Overlap?” Trans. R. Soc. Trop. Med. Hyg. 109 (2015): 609-618. PubMed: 26286946.

Image:  Larvae of Culex Mosquitoes (CDC/James Gathany)


Pathogenic and Opportunistic Free-Living Amoebae
Highlights

Acanthamoeba spp., Balamuthia mandrillaris and Naegleria fowleri are free-living amoebae inhabiting a wide variety of environmental niches worldwide, with the potential to cause infections in both humans and animals.

Acanthamoeba spp. and B. mandrillaris are opportunistic pathogens of the central nervous system, lungs, sinuses and skin, primarily in immunocompromised patients and, in severe cases, lead to the fatal disease granulomatous amebic encephalitis.1-3 Among individuals wearing contact lenses, Acanthamoeba spp. is the causative agent of the sight-threatening infection Acanthamoeba keratitis.3 In contrast, N. fowleri, commonly known as the “brain-eating amoeba”, is pathogenic in healthy humans, causing acute and fulminant primary amoebic meningoencephalitis, a water-borne disease of the central nervous system resulting in extensive tissue damage, inflammation and hemorrhagic necrosis.4 Infection with N. fowleri is primarily associated with recreational activities in freshwater lakes and reservoirs naturally heated by the sun, as well as in geothermal sources and water thermally polluted by industry.3,4

The availability of clinical isolates is essential for the advancement of research into the biology, mechanisms of pathogenesis, immunology, antimicrobial susceptibility and molecular characteristics of these amoebae. BEI Resources maintains a collection of free-living amoeba, currently totaling 50 isolates, deposited by the Free-Living & Intestinal Amebas Laboratory, Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention. Each isolate is cataloged with the geographical location, year and source of isolation and reported genotype. Please visit the BEI Resources website for a complete list of isolates in our free-living amoeba catalog.

References:

  1. Marciano-Cabral, F. and G. Cabral. ”Acanthamoeba spp. as Agents of Disease in Humans.” Clin. Microbiol. Rev. 16 (2003): 273-307. PubMed: 12692099.
  2. Cope, J. R., et al. “The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the United States, 1974-2016.” Clin. Infect. Dis. 68 (2019): 1815-1822. PubMed: 30239654.
  3. Visvesvara, G. S. “Amebic Meningoencephalitides and Keratitis: Challenges in Diagnosis and Treatment.” Curr. Opin. Infect. Dis. 23 (2010): 590-594. PubMed: 20802332.
  4. Siddiqui, R., et al. “Biology and Pathogenesis of Naegleria fowleri.” Acta Trop. 164 (2016): 375-394. PubMed: 27616699.

Image:  Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri (BEI Resources)


Invasive Longhorned Ticks Now Available
Highlights

The “Asian Longhorned Tick”, Haemaphysalis longicornis, is invasive in the United States, first identified in New Jersey in 2017, and is rapidly spreading. While human pathogens have not yet been identified within H. longicornis found within the United States, the vector is known to be competent for transmission of a number of zoonotic tick-borne disease pathogens, including Borrelia, Rickettsia, Erlichia and Anaplasma species, Powassan virus and several Babesia parasites.1-4 In China, H. longicornis is a vector of the severe fever with thrombocytopenia syndrome (SFTS) virus, an emerging phlebovirus with high mortality rates.5

H. longicornis is especially of agricultural concern with cattle and sheep, transmitting tropical theileriosis, a potentially fatal parasitic infection in cattle in southern Europe, Africa and Asia. In sheep, H. longicornis infestation impacts both the quality and quantity of wool. This disease host is known to be difficult to control and is unique among ticks in the ability of the females to reproduce by parthenogenesis (full development of unfertilized eggs), as well as by sexual reproduction.

As of August 1, 2019, Asian longhorned ticks have spread to nearly one quarter of the United States, affecting Arkansas, Connecticut, Delaware, Kentucky, Maryland, North Carolina, New Jersey, New York, Pennsylvania, Tennessee, Virginia and West Virginia.6

The newly available H. longicornis colony established from a wild-type, parthenogenic strain deposited by Dr. Michael Levin, Centers for Disease Control and Prevention, is confirmed specific-pathogen-free (SPF) by molecular screening and is available to qualified insectaries in the larval, nymph and adult life stages:

   
BEI Resources No. Product Description
NR-51846 Haemaphysalis longicornis Adult - live, wild-type adult tick
NR-51847 Haemaphysalis longicornis Larvae - live, wild-type larval batch
NR-51848 Haemaphysalis longicornis Nymph - live, wild-type nymph

 

References:

  1. Lee, M.-J. and Joon-Seok Chae. “Molecular Detection of Erhlichia chaffeensis and Anaplasma bovis in the Salivary Glands from Haemaphysalis longicornis Ticks.” Vector Borne Zoonotic Dis. 10 (2010): 411-413. PubMed: 19874189.
  2. Meng, Z., et al. “[Detection of Co-Infection with Lyme Spirochetes and Spotted Fever Group Rickettsiae in a Group of Haemaphysalis longicornis].” Zhonghua Liu Xing Bing Xue Za Zhi [Chinese Journal of Epidemiology] 29 (2008): 1217-1220. PubMed: 19173967.
  3. Hoogstraal, H. “Changing Patterns of Tickborne Diseases in Modern Society.” Annu. Rev. Entomol. 26 (1981): 75-99. PubMed: 7023373.
  4. Heath, A. C. G. “Vector Competence of Haemaphysalis longicornis with Particular Reference to Blood Parasites.” Surveillance 29 (2002): 12-14. http://www.sciquest.org.nz/node/47255.
  5. Yu, X. J., et al. “Fever with Thrombocytopenia Associated with a Novel Bunyavirus in China.” N. Engl. J. Med. 364 (2011): 1523-1532. PubMed: 21410387.
  6. “What You Need to Know About Asian Longhorned Ticks - A New Tick in the United States.” Centers for Disease Control and Prevention, U. S. Department of Health and Human Services, //www.cdc.gov/ticks/longhorned-tick/index.html.

Image:  Adult female Haemaphysalis longicornis tick (CDC/James Gathany)


New reference reagents for Zika virus
Highlights

Now available are two well-characterized reference reagents for Zika virus (ZIKV) to facilitate evaluation of existing nucleic acid testing (NAT) assays and development of novel ZIKV assays. These reagents were produced by The Center for Biologics Evaluation and Research/U.S. Food and Drug Administration (CBER/FDA) from heat-inactivated (HI) ZIKV culture supernatant stock from two strains, PRVABC59 and FSS13025, which were diluted in dialyzed, defibrinated human plasma, and lyophilized. These reagents add to the expansive catalog of Zika virus materials now available from BEI Resources.

Image:  Female Aedes aegypti mosquito (CDC/James Gathany)


Reference strains of Coccidioides spp.
Highlights

Coccidioidomycosis, also known as Valley fever, is an invasive fungal infection caused by the dimorphic fungi Coccidioides immitis and Coccidioides posadasii. These fungi are endemic to arid or semi-arid regions of the southwestern United Sates, Mexico, and Central and South America. Infection is acquired through inhalation of air-dispersed fungal spores termed arthroconidia. The initial or acute form of coccidioidomycosis is often mild with symptoms such as fever, cough, chest pain, and red, spotty rash. If infection is not controlled, it may progress to chronic pneumonia or even disseminate to other parts of the body including the brain, especially in immunocompromised patients. BEI Resources houses a well-characterized collection of Coccidioides strains from various origins, which have been used in studies of the ecology and distribution of different genotypes of the pathogen. Such studies are important for monitoring outbreaks, determining changes in virulence, and predicting disease progression. These strains were generously contributed by Dr. Bridget Barker, Northern Arizona University.

Image:  Colonies of Coccidioides immitis, Strain RMSCC 3476 (NR-48939) growing at 37°C on Emmons' Modification of Sabouraud agar.


New Luciferase-Expressing strains of Leishmania mexicana and Trypanosoma cruzi
Highlights

BEI Resources continues to expand the catalog of luciferase-expressing parasitic protists. Recent additions include Leishmania mexicana, strain MNYC/BZ/62/M379 transfected with the luciferase gene from the sea pansy Renilla reniformis (NR-51210) and Trypanosoma cruzi, strain CL Brener expressing the thermostable red-shifted luciferase gene mutant, PpyRE9 (NR-49161). These models allow the high-throughput screening of large numbers of candidate compounds during infection in vitro and the possibility of tracking parasite distribution in vivo in laboratory mice. The expression of red-shifted luciferase in T. cruzi, in particular, results in a reporter system that is more sensitive than other bioluminescence systems previously reported. The availability of these new transgenic strains provides the researcher rapid quantification of parasite growth and simplification of the methodology for scoring inhibitor assays.

Reference:

Lewis, M.D., et al. “A New Experimental Model for Assessing Drug Efficacy Against Trypanosoma cruzi Infection Based on Highly Sensitive in vivo Imaging.” J. Biomol. Screen. 20 (2015): 36-43. PubMed: 25296657.

 

Image:  Trypanosoma cruzi CL Brener PpyRE9 (NR-49161) epimastigotes stained with GIEMSA (BEI Resources)


Exempt Burkholderia pseudomallei strain Now Available
Highlights

Burkholderia pseudomallei, the causative agent for melliodiosis, is an opportunistic pathogen found in soil in tropic and subtropic regions worldwide.  B. pseudomallei is classified as a category B, Tier 1 Select Agent in the United States due to a high mortality rate when untreated, and the potential for its use as a biowarfare agent through aerosol transmission. Most strains of B. pseudomallei require handling under Biosafety level 3 (BSL 3). B. pseudomallei, strain Bp82 (deltapurM) has a 109 base pair deletion within the purM open reading frame, rendering the strain avirulent in mouse and hamster models.  B. pseudomallei, strain Bp82 (deltapurM) is now an Excluded Strain from the HHS and USDA Select Agents and Toxins ­Exclusions list and can be handled under BSL 2 conditions. Strain Bp82 (deltapurM) has been proposed as a vaccine candidate and has been used in antibiotic resistance studies.  This strain was graciously deposited into BEI Resources by Dr. Herbert Schweizer, and is available as item number NR-51280.

Reference:

Propst, K. L., et al. “A Burkholderia pseudomallei deltapurM Mutant is Avirulent in Immunocompetent and Immunodeficient Animals: Candidate Strain for Exclusion from Select-Agent Lists.” Infect. Immun. 78 (2010): 3136-3143. PubMed: 20404077.

Image:  Burkholderia pseudomallei culture on sheep blood agar (CDC/ Larry Stauffer)



Enterovirus and Acute Flaccid Myelitis Research Materials

Figure 1: Human rhabdomyosarcoma (RD) cells (ATCC® CCL-136™) infected with EV-D68, US/MO/14-18947 (BEI Resources NR-49129) showing signs of cytopathic effect in the right panel. The left panel shows mock infected cells. Magnification 10x brightfield.

In support of Enterovirus D68 (EV-D68) vaccine development research, BEI Resources has performed initial screening of cell lines amenable for human vaccine development. The following study assesses the suitability of cell lines for virus propagation in the presence of serum and after adaptation to serum free (SF) conditions. A guidance on how to adapt cell lines to serum free media is provided.

Enterovirus and Acute Flaccid Myelitis
Enterovirus D68 (EV-D68) has reemerged as a cause of severe respiratory infections in young children around the world and as a newly emerged neuropathogenic threat. First isolated in the United States (US) from children with serious respiratory illness in 19621, only sporadic clusters of EV-D68 infection were reported globally in the last decade2 until 2014 when an unusually large outbreak occurred in the US. During this outbreak (and in subsequent 2016 and 2018 outbreaks), a subset of children with laboratory confirmed EV-D68 related severe respiratory illness also developed an acute flaccid myelitis (AFM). Detection of virus in the spinal fluid of AFM affected children3 is rare but recently, researchers have found new evidence linking AFM to enteroviruses due to the presence of higher levels of EV specific antibodies in cerebrospinal fluid of children with AFM compared to non-AFM controls4,5.

BEI Resources Screening of Cell Lines for EV-D68 Propagation in Media Supplemented with Serum
Typically, EV-D68 is propagated in human rhabdomyosarcoma (RD) cells (ATCC® CCL-136™) at 33°C. However, this cell line is not amenable for vaccine production and additionally is maintained in serum containing media. Consequently, BEI Resources has performed an initial screen of suitable cell substrates for EV-D68 vaccine development. Five cell lines were tested for EV-D68 susceptibility and production rates to assess the successful propagation using two EV-D68 isolates originally grown in RD cells that are available in BEI Resources (see Table 1 for details).

Prior to infection, the cell lines were maintained at 37°C. Viral growth media contained 2% fetal bovine serum (FBS) (ATCC® 30-2020™) and the ATCC® recommended base media for each cell line (Table 1). The cells were infected with each viral strain using a multiplicity of infection (MOI) of 0.01 and incubated at 33°C. When approximately 90% of the cells showed cytopathic effect (CPE), the virus was harvested by scraping the monolayer into the supernatant. The infected cell lysate was clarified by centrifugation at 2400g and the pellet underwent three freeze-thaw cycles to release the virus which was then added back to the supernatant. The viruses were titrated in RD cells by the 50% Tissue Culture Infectious Dose (TCID50) method and calculated by the Reed-Muench method. If a virus infected cell line displayed no signs of CPE after an extended incubation period of 12-14 days, the absence of virus was confirmed by performing an immunofluorescence assay (IFA) with a virus specific antibody. Furthermore, they underwent two blind passages with extended incubation to confirm that the cell line did not support growth of the virus. All infected cell lines were subjected to three total serial passages with the second and third passage utilizing a 1:100 dilution of virus inoculum in media rather than MOI. For a direct comparison of virus susceptible cell lines using MOI for passage 1, virus titration was performed RD cell line (Table 1).

The cells lines A549, MRC-5 and HEK-293 T/17 support growth of both EV-D68 viral isolates. These results are comparable to the same viral isolates grown in RD cells. HEK-293 cells supported growth of US/MO/14 18947 but showed reduced virus fitness for the three passages tested and did not support growth of the US/KY/14-18953 virus. CHO cells expressing the ICAM-1 receptor was not susceptible to the two isolates used in the cell screening assessments.
 

Table 1. Susceptibility of five cell lines growth in media containing 2% FBS using two EV-D68 isolates

Cell line

Virus growth media
(Base Media) + 2% FBS

Virus isolates *

Passage 1 Titer
(in RD cells)

 Control: RD cells

 (ATCC® CCL-136™)

 DMEM

 (ATCC® 30-2002)

 US/MO/14-18947

 1.58 x107

 US/KY/14-18953

 1.58x107

 MRC-5

 (ATCC® CCL-171™)

 EMEM

 (ATCC® 30-2003)

 US/MO/14-18947

 1.58x107

 US/KY/14-18953

 8.89x106

 A549

 (ATCC® CCL-185™)

 F-12K

 (ATCC® 30-2004)

 US/MO/14-18947

 1.58x107

 US/KY/14-18953

 8.89x105

 HEK-293 T/17

 (ATCC® CRL-11268™)

 DMEM

 (ATCC® 30-2002)

 US/MO/14-18947

 2.81x107

 US/KY/14-18953

 1.58x106

 HEK-293

 (ATCC® CRL-1573™)

 EMEM

 (ATCC® 30-2003)

 US/MO/14-18947

 4.5x104

 US/KY/14-18953

 No growth

 CHO-ICAM-1

 (ATCC® CRL-2093™)

 RPMI-1640

 (ATCC® 30-2001)

 US/MO/14-18947

 No growth

 US/KY/14-18953

 No growth

*US/MO/14-18947 is available in the BEI Resources catalog as NR-49129 and US/KY/14-18953 as NR-49132


BEI Resources Screening of Cell Lines for EV-D68 Propagation in Serum Free Media
BEI Resources performed a second screen of cell lines under serum free conditions to assess the growth of EV-D68 . Four of the cell lines (MRC-5, A549 and HEK-293 T/17 and 293) were adapted to grow in serum free conditions by weaning serum and switching into chemically defined media with supplements . All the cell lines were grown in viral growth media (base media recommended for each cell line) supplemented with 2% FBS to serve as controls. An additional control included use of RD cells grown in base media with 2% serum. (see Table 2 for details)

Serum Free (SF) adapted cell lines were grown in appropriate growth media at 37°C and infected with the EV-D68 isolate US/MO/14-18947 at a MOI of 0.001. All cell lines were incubated at 33°C for three passages with each successive passage infected at MOI of 0.001. All control cell lines were similarly infected. At the end of each passage virus from all cell lines were titrated (see Table 2). Note that viral titers were determined by a standard assay using RD cells.
 

Table 2. Comparison of EV-D68 growth in cell lines adapted to serum free conditions
Cell Line Media Titration in RD Cells
Passage 1 Passage 2 Passage 3

 Control: RD cells

 DMEM (+2% FBS)  1.58x107  8.89x106  5.0x106

 MFC-5

 

 EMEM (+2% FBS)  8.89x106  5.0x106  1.58x106
 SF media: PC-1 media  2.81x106  1.58x106  1.58x106

 A549

 

 F-12K (+2% FBS)  2.81x107  1.58x107  2.81x107
 SF media: PC-1 media  1.58x107  2.81x106  2.81x106
 HEK-293 T/17

 DMEM (+2% FBS)

 8.89x107  2.81x107  1.58x107

 SF media: EX-CELL®
 293 Serum-Free Media

 2.81x103  8.89x105  2.81x106

 

Infection and viral production of the EV-D68 US/MO/14-18947 virus isolate was successful over the course of three passages in serum free conditions for three cell lines, A549, MRC-5, and HEK-293 T/17, however HEK-293 did not support the growth of the virus. The CPE for HEK-293 T/17 in SF adapted cells is difficult to discern as the cells lose anchorage dependence. As a result, confirmation of viral infection in HEK-293 T/17 SF adapted cells requires IFA.

Summary of BEI Resources Cell Screening for EV-D68 Propagation
Using two EV-D68 isolates, it was observed that two cell lines A549 and MRC-5 successfully supported virus growth after adaptation to serum-free conditions for use in downstream vaccine developmental needs. Both the cell lines were found to be robust and tolerated the serum weaning process while maintaining their morphology and viability.

For guidance and protocols on serum free adaptation of cell lines A549, MRC-5, HEK-293 and HEK-293 T/17, please visit our Knowledge Base.

For information on the availability of virus isolates grown in serum free A549 adapted cells, please email Contact@BEIResources.org.
 

To support your Enterovirus research, BEI Resources has several isolates available
NR-51430 Enterovirus D68, Fermon          
NR-51844 Enterovirus D68, USA/MO-18949 mouse-adapted
NR-51845 Enterovirus 71, Tainan/4643/98 mouse-adapted          
NR-51996 Enterovirus D68, USA/2018-23087          
NR-51997 Enterovirus D68, USA/2018-23088          
NR-51998 Enterovirus D68, USA/2018-23089 
NR-51999 Enterovirus A71, USA/WA/2016-19522
NR-52000 Enterovirus A71, USA/2018-23092
NR-52009 Plasmid pBR322 Containing cDNA from Enterovirus D68, US/MO/14-18947, Infectious Clone pBR-49129
NR-52010 Plasmid pUC19 Containing cDNA from Enterovirus D68, US/MO/14-18949, Infectious Clone pUC-49130
NR-52011 Plasmid pUC19 Containing cDNA from Enterovirus D68, US/IL/14-18952, Infectious Clone pUC-49131
NR-52013 Enterovirus D68 US/MO/14-18947 (produced in serum-free A549 cells)
NR-52014 Enterovirus D68 US/KY/14-18953 (produced in serum-free A549 cells)
NR-52015 Enterovirus D68, USA/2018-23087 (produced in serum-free A549 cells)
NR-52016 Enterovirus D68, USA/2018-23088 (produced in serum-free A549 cells)
NR-52017 Enterovirus D68, USA/2018-23089 (produced in serum-free A549 cells)
NR-52268 Homo sapiens Lung Carcinoma Cells (A549), Serum-Free
NR-52353 Enterovirus D68, USA/2018-23201 (produced in serum-free A549 cells)
NR-52354 Enterovirus D68, USA/2018-23263 (produced in serum-free A549 cells)
NR-52356 Enterovirus D68, USA/2018-23209 (produced in serum-free A549 cells)
NR-52357 Enterovirus D68, USA/2018-23216 (produced in serum-free A549 cells)
NR-52375 Plasmid pUC19 Containing cDNA from Enterovirus D68, USA/Fermon, Clone EV-D68-R-Fermon
NR-52377 Plasmid pUC57-Simple Containing cDNA from Enterovirus D68, USA/WI/2009-23230, Infectious Clone EV-D68-R23230
NR-52378 Plasmid pUC57-Simple Containing cDNA from Enterovirus D68, USA/FL/2016-19504, Infectious Clone EV-D68-R19504
NR-52379 Plasmid pUC57-Simple Containing cDNA from Enterovirus D68, USA/2018-23088, Infectious Clone EV-D68-R23088
NR-52380 Plasmid pUC57-Simple Containing cDNA from Enterovirus D68, USA/IL/2018-23252, Infectious Clone EV-D68-R23252
NR-471 Human Enterovirus 71, Tainan/4643/1998
NR-472 Human Enterovirus 71, MP4
NR-49129 Enterovirus D68, US/MO/14-18947
NR-49130 Enterovirus D68, US/MO/14-18949
NR-49131 Enterovirus D68, US/IL/14-18952
NR-49132 Enterovirus D68, US/KY/14-18953
NR-49133 Enterovirus D68, US/IL/14-18956
NR-4960 Genomic RNA from Human Enterovirus 71, Tainan/4643/1998
NR-4961 Genomic RNA from Human Enterovirus 71, MP4
NR-49134 Genomic RNA from Enterovirus D68, US/MO/14-18947
NR-49135 Genomic RNA from Enterovirus D68, US/MO/14-18949
NR-49136 Genomic RNA from Enterovirus D68, US/IL/14-18952
NR-49137 Genomic RNA from Enterovirus D68, US/KY/14-18953
NR-49138 Genomic RNA from Enterovirus D68, US/IL/14-18956

 

Coming Soon - Available in Winter of 2020/2021 
NR-52376        Plasmid, Enterovirus D68, USA/1989-23220 (molecular clone)
NR-52355        Enterovirus D68, USA/2018-23206 (produced in serum-free A549 cells)

 


References

1.            Schieble JH et al. 1967. A probable new human picornavirus associated with respiratory diseases. Am J Epidemiol 85:297–310.

2.            Eshaghi A et al. 2017. Global Distribution and Evolutionary History of Enterovirus D68, with Emphasis on the 2014 Outbreak in Ontario, Canada. Front Microbiol. 8:257.

3.            https://www.cdc.gov/non-polio-enterovirus/about/ev-d68.html#seasonal-circulation

4.            Mishra N et al. 2019. Antibodies to enteroviruses in cerebrospinal fluid of patients with acute flaccid myelitis. mBio 10:e01903-19.

5.            Schubert RD et al. 2019. Pan-viral serology implicates enteroviruses in acute flaccid myelitis. Nat Med 25: 1748–1752

 


Monoclonal antibodies to Trypanosoma cruzi
Highlights

Chagas’ disease caused by the protozoan parasite Trypanosoma cruzi (T. cruzi) is widespread in Central and South America infecting an estimated 12 to 14 million people, with infection often leading to chronic myocarditis resulting in high morbidity and mortality. In addition to our catalog of T. cruzi parasites and triatomine vectors, BEI Resources now offers monoclonal antibodies raised against parasite stage-specific surface antigens, which play important roles during infection. These antigens include the trypomastigote-specific antigen Ssp-1 (BEI Resources NR-50891) and the amastigote-specific surface antigen Ssp-4 (BEI Resources NR-50892). Studies have shown the presence of Ssp-4 in tissue culture supernatants of T. cruzi-infected cells and the presence of anti-Ssp4 antibodies in sera from chagasic patients. These monoclonal antibodies were generously contributed by Dr. Norma Andrews, University of Maryland.  Dr. Andrews generated these monoclonal antibodies while at the laboratory of Dr. Ruth Nussenzweig, New York University.
Image:  Immunofluorescence staining of amastigotes of Trypanosoma cruzi, strain TcVT-1 (BEI Resources NR-36630) with Monoclonal Anti-Trypanosoma cruzi, NR-50892. A, Light microscopy image of T. cruzi-infected kidney epithelial cells (ATCC® CCL-26™). B, Immunostaining of intracellular amastigotes with NR-50892 labeled with a FITC-conjugated rabbit anti-mouse antibody. Host cell and parasite nuclei are stained with DAPI.

References:

  1. Andrews, N. W., et al. “Stage-Specific Surface Antigens Expressed during the Morphogenesis of Vertebrate Forms of Trypanosoma cruzi.”  Exp. Parasitol. 64 (1987):  474-484.  PubMed:  3315736.
  2. Andrews, N. W., et al. “Developmentally Regulated, Phospholipase C-Mediated Release of the Major Surface Glycoprotein of Amastigotes of Trypanosoma cruzi.”  167 (1988):  300-314.  PubMed:  3279152.

Enterobacter cloacae complex isolates for antibiotic resistance studies
Highlights

Enterobacter cloacae is part of the normal human flora and not considered a primary pathogen. Unfortunately, there is increasing incidence of nosocomial infections with E. cloacae, which frequently involve intravenous and other medical and hospital devices as well as medical solutions and disinfectants used routinely in hospitals and patient care facilities. The situation is further complicated by the ability of these bacteria to acquire resistance to antibiotics, notably carbapenems. BEI Resources has obtained a set of 15 isolates of the E. cloacae complex with defined susceptibility patterns against 16 antibiotics. This valuable set is now available to aid your studies on carbapenem-resistant Enterobacteriaceae (CRE).

BEI Resources No. Description
NR-50391 Enterobacter cloacaecomplex strain BEI01
NR-50392 Enterobacter cloacaecomplex strain BEI02
NR-50393 Enterobacter cloacaecomplex strain BEI03
NR-50394 Enterobacter cloacaecomplex strain BEI04
NR-50395 Enterobacter cloacaecomplex strain BEI05
NR-50396 Enterobacter cloacaecomplex strain BEI06
NR-50397 Enterobacter cloacaecomplex strain BEI07
NR-50398 Enterobacter cloacaecomplex strain BEI08
NR-50399 Enterobacter cloacaecomplex strain BEI09
NR-50400 Enterobacter cloacaecomplex strain BEI10
NR-50401 Enterobacter cloacaecomplex strain BEI11
NR-50402 Enterobacter cloacaecomplex strain BEI12
NR-50403 Enterobacter cloacaecomplex strain BEI13
NR-50404 Enterobacter cloacaecomplex strain BEI14
NR-50405 Enterobacter cloacaecomplex strain BEI15

Mayaro and Una Viruses Now Available
Highlights

Mayaro virus (MAYV) is a New World alphavirus and the etiologic agent of Mayaro fever, an acute febrile illness sometimes accompanied by severe and persistent arthritis similar to Chikungunya fever. Its transmission cycle occurs mainly through mosquito vectors, especially those of the genus Haemagogus, but Aedes spp. mosquitoes may also be competent vectors. The enzootic transmission cycle of MAYV is not fully understood, but the occurrence of relatively large outbreaks of Mayaro fever and the competence of Aedes mosquitoes for the transmission of MAYV suggest the potential for an urban human-mosquito-human transmission cycle to emerge. MAYV was first isolated in Trinidad in 1954, with sporadic outbreaks of Mayaro fever in Bolivia, Brazil, and other regions throughout Central and South America. Recently, MAYV was found in a DENV co-infected patient in Haiti1, the first report of MAYV in the Caribbean nation, underscoring the need for MAYV inclusion in surveillance activities in these regions in addition to Dengue, Chikungunya, and Zika viruses.

Una virus (UNAV) is the closest genetic relative of MAYV that also causes a similar febrile illness. UNAV was first identified in northern Brazil in 1959. Serosurveys have identified antibodies against UNAV in birds, horses, and humans; however, the extent of viral distribution and human disease risk is unknown.

References:1. eid2211.161015


Plasmid stability in Staphylococcus without antibiotic selection?
Highlights

Plasmid maintenance by bacteria can be unpredictable without selective pressure. This is of particular concern during in vivo studies. To circumvent this in Staphylococcus species, the Bose Lab at The University of Kansas Medical Center has provided plasmids to BEI Resources that remain stable inStaphylococcus cells without the requirement of antibiotics during both in vitro and in vivo experiments1. These E. coli-S. aureus shuttle vectors are based on the LAC-p01 plasmid.

Plasmid pKK22 (Accession KX085042) is designed to be used with S. aureus USA300 strains that contain LAC-p01 and will render the strains isogenic. Plasmid pKK30 (Accession KX085043) is a variant of pKK22, in which the predicted open reading frames (ORFs) that are not needed for plasmid maintenance have been deleted, and is intended for use inStaphylococcus cells that do not contain LAC-p01. Both plasmids contain a single trimethoprim resistance cassette that is functional in both E. coliand Staphylococcus. In addition, they contain the E. coli R6Kγ origin of replication and require pir+ cells for replication. DH5αλpir and the pir+dam- dcm- strain GM2163λpir are provided as a host strains, courtesy of Dr. Eric Stabb (University of Georgia)2. These plasmids and host strains are now supplied individually or as a kit through BEI Resources.

BEI Resources No. Description
NR-50348 Escherichia coli DH5αλpir containing pKK22
NR-50349 Escherichia coli DH5αλpir containing pKK30
NR-50350 Escherichia coli DH5αλpir
NR-50351 Escherichia coli GM2163λpir
NR-50352 Kit: In vivo stable Staphylococcus plasmids and E. coli hosts

References:

1. Krute, C. N., K. K. Krausz, M. A. Markiewicz, J. A. Joyner, S. Pokhrel, P. R. Hall, and J. L. Bose. 2016. "Generation of a Stable Plasmid for in vitro and in vivostudies of Staphylococcus." Applied and Environmental Microbiology 82:6859-6869. PMID 27637878

2. Dunn A. K., M. O. Martin, and E. V. Stabb. 2005. "Characterization of pES213, a Small Mobilizable Plasmid from Vibrio fischeri." Plasmid 54:114-134. PMID: 16122560


Clostridium difficile research is easier with strains from BEI Resources
Highlights

Clostridium difficile research is easier with strains from BEI Resources

Clostridium difficile (also known as Peptoclostridium difficile) is an increasingly common opportunistic pathogen that causes diarrhea and more serious intestinal conditions such as colitis. It is commonly observed in patients that have an illness that requires prolonged use of antibiotics, or can be acquired in hospitals and long-term care facilities. C. difficile infections are normally treated with antibiotics; however, this is particularly problematic due to the high levels of antibiotic resistance displayed by these bacteria. Recent studies have shown that replenishment of the normal gut microbiota provides a successful tool to control the infection with C. difficile.
BEI Resources has a large number of C. difficile strains, as well as nucleic acids, toxins, and other reagents available for your research (please click here for a list).
Among the bacterial strains, several have well characterized tcdA, tcdB, and cdtB toxin

Viral nucleic acids
Highlights

For the benefit of researchers requiring nucleic acids from pathogens, BEI Resources offer more than 1,000 nucleic acids derived from pathogens. These reagents can be used at lower containment levels for molecular studies; to ensure their biosafety, the preparations have been safety tested for the absence of residual live organisms. Please check our website to see the wide variety viral nucleic acids extracted from various BSL-2 through BSL-4 pathogens. Notable new additions to this category of reagents include Genomic RNA from Enterovirus D68 and human metapneumovirus.


Give a whooping push to your research
Highlights

Whooping cough is a disease caused by bacteria from the genus Bordetella. Currently under widespread resurgence, whooping cough ranks globally among the 10 leading causes of childhood mortality. BEI Resources offers several isolates of Bordetella pertussis, B. bronchiseptica, and B. holmesii, along with toxins, nucleic acids, and proteins for Bordetella research. To see the full list of Bordetella reagents and strains currently available from BEI resources, please click here

 

Image:  Bordetella holmesii NR-43499 grown on Bordet Gengou media


Toxoplasma gondii
Highlights

Toxoplasma gondii is an obligate intracellular protozoan parasite of the phylum Apicomplexa that is the causal agent of toxoplasmosis. BEI Resources houses a comprehensive assortment of T. gondii cultures that include GFP-expressing strains; reference genome strains; genetic crosses between type strains I, II, and III; and strains used as models for parasite transmission and cyst formation. For a complete list of our Toxoplasma catalog, please contact us at Contact@BEIResources.org.

BEI Resources Number

Comment

Strain

NR-743

Transgenic RH strain expressing GFP

RH-GFP 5 S65T

NR-744

Transgenic PTG strain expressing GFP

PTG-GFP 5 S65T

NR-10150 - NR-10170

Genetic crosses between strain types II and III

Various

NR-10238 - NR-10273

Genetic crosses between strain types I and III

Various

NR-49173 - NR-491991

Genetic crosses between strain types I and II

Various

NR-20728 - NR-20739

Reference genome strains for haplogroups 1 through 15

Various

NR-15248

Mutant RH strain deficient in the ku80 and hxgprt genes

RH∆ku80∆hxg

NR-43998

Pig, Massachusetts, 2002; cat-to-cat transmission studies

Dubey

NR-44106

Recombinant type I/III; forms cysts spontaneously in vitro

EGS

1 Available soon. Send inquiries to Contact@BEIResources.org for availability.

 


Staphylococcus gene expression analysis shuttle vectors for pathogenesis studies
Highlights

BEI Resources offers 42 distinct Escherichia coli-Staphylococcus cassette-based shuttle vectors that provide all the tools you need to complete your research. These shuttle vectors are deposited as part of the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) reagents. Choose from staphylococcal low-copy-number, high-copynumber, thermosensitive, and theta-replicating plasmids. Select from erythromycin, tetracycline, chloramphenicol, kanamycin, or spectinomycin selectable markers in Staphylococcus, and ampicillin, erythromycin, kanamycin, and chloramphenicol resistance markers in E. coli. The modular design of the plasmid vector system offers flexibility and variety for expression analysis and provides the opportunity to address questions about gene dosage, complementation, and cis-trans effects. The shuttle vector system provides effective tools for studying gene regulation of staphylococci among ecosystems.

For further published details on these plasmids, please see Charpentier et al. Appl

Environ Microbiol 70(10): 6076-6085, 2004

Image:  NR-46158. Staphylococcus aureus strain 4221 containing shuttle vector pCN57, grown on TSA + 10 μg/ml erythromycin

.


Genome Sequenced Clinical and Contaminated Yogurt Isolates of Mucor circinelloides f. circinelloides
HighlightsTwo genome sequenced isolates of Mucor circinelloides f. circinelloides (NR-49108 Strain designation 1006PhL, and NR-49117 Strain designation Mucho) are now available from BEI Resources. Mucor circinelloides f. circinelloides is surpassed only by Rhizopus species as the most common cause of mucormycosis, and is the most virulent of the Mucor circinelloides species. One isolate was obtained from the skin of a healthy individual, and the other from contaminated yogurt responsible for the 2013 Mucorales outbreak.

Filoviral expression plasmids
Highlights

We have a number of expression plasmids for various Filoviral proteins for Zaire Ebolavirus and Marburgvirus. Many of the proteins have been tagged with HA or FLAG. Continue to check our catalog for new plasmid additions, such as those expressing GP, NP, VP24, VP30, VP35, and VP40 in the next few months for a complete list.


Pathogenic amoebae that affect human health
 

Staphylococcus aureus

Entamoeba histolytica

Pathogenic amoebae that affect human health

Amoebae are a diverse group of protists that move primarily by extending and retracting pseudopodia. The most important pathogenic amoeba for humans is Entamoeba histolytica. Among the free-living amoebae that exist in nature, Acanthamoeba spp. and Naegleria fowleri belong to a handful of genera that have an association with human disease. BEI Resources houses a diversity of pathogenic amoeba strains for researchers working on mechanisms of pathogenesis, diagnostics, antimicrobial sensitivity, and the molecular biology of these organisms.

Entamoeba histolytica. Entamoeba histolytica is an enteric parasite that predominantly infects humans and other primates. Most infections are asymptomatic and tissue invasion is a rare occurrence. In some cases, diseases can range from chronic, mild diarrhea, to fulminant dysentery. For a list of E. histolytica strains available at BEI Resources click here.

Acanthamoeba spp. Acanthamoebae inhabit a wide variety of environmental niches. In healthy humans, Acanthamoeba can cause a sight-threatening eye disease known as Acanthamoeba keratitis. In immunocompromised individuals, Acanthamoeba can cause disseminated infections and the fatal disease granulomatous amebic encephalitis. For a list of Acanthamoeba spp. strains available at BEI Resources click here.

Naegleria fowleri. Naegleria fowleri is the causative agent of primary amoebic meningoencephalitis (PAM) in humans. The disease is rare yet so fulminant that few people survive infection. Cases of PAM reported in North America usually occur after swimming in water naturally heated by the sun. For a list of Naegleria fowleri strains available at BEI Resources click here.

 

New Updates to MR4 Methods Manuals

Anopheles mosquito. Photo courtesy of James Gathany and CDC

Anopheles mosquito. Photo courtesy of James Gathany and CDC.

New Updates to MR4’s “Methods in Anopheles Research” and “Methods in Malaria Research” Laboratory Manuals - Now Available for Free Download

Our friends at the CDC have updated the frequently-accessed and freely available MR4 Methods in Anopheles Research laboratory manual, which provides detailed insectary and benchtop protocols for rearing, genotyping, and phenotyping Anopheline and other mosquito vector colonies, as well as information on field techniques, insecticide resistance, screening for Wolbachia infection, and an introduction to Aedes and Culex colony methodology. 

What’s more, a revised and expanded edition of EVIMalR and MR4’s extremely popular “Methods in Malaria Research” laboratory manual was also recently released. The updated manual provides a wide variety of protocols for in vitro, in vivo, antimalarial drug screening, and transmission research on Plasmodium spp., and the use of parasite genome databases to incorporate bioinformatics. 


Transposon library mutants available
 

Transposon Library Mutants

NR-46829. Staphylococcus aureus JE2 transposon mutant SAUSA300_0113 grown on TSB + 5 µg/mL erythromycin

Transposon library mutants available to study non-essential genes of Staphylococcus aureus

As part of the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA), BEI Resources is supplying the scientific community with the Nebraska Transposon Mutant Library (NTML). The NTML is an assortment of sequence-defined transposon insertion mutants of S. aureus strain USA300 LAC. Each clone harbors a different non-essential gene disrupted by the insertion of the mariner-based transposon bursa aurealis. The exact location of each transposon insertion in each of the 1955 clones is available from the University of Nebraska Medical Center. Most of these clones are grown when ordered (made to order), please allow time for production and testing by BEI Resources when ordering.


Human Metapneumovirus

Human Metapneumovirus

BEI Resources announces the addition of human metapneumovirus (hMPV) isolates, dating from 1983, to our vast assortment of viruses. hMPV was isolated from young children with acute respiratory tract disease in the Netherlands in 2001, and is now recognized as a major cause of respiratory illness in infants and children worldwide. hMPV is difficult to grow in cell culture, largely explaining the delay in recognizing this pathogen, which has been causing disease for half a century as evidenced by retrospective serological analyses. Please check our Knowledge Base query box using keyword “metapneumovirus” for tips on how to successfully propagate the virus in cell culture.


Welcome NARSA Researchers!
Highlights
The NARSA Strain Repository is transitioning to BEI Resources, NIAID's centralized research reagent repository in May 2014. Due to this transition, Eurofins will no longer be registering users after March 14th, 2014. Eurofins will no longer be taking orders in May.  All orders after May 23rd, 2014, should be made through BEI Resources.

Registration for the BEI Resources program can be found at this link below. NARSA Strain requestors will need to register for Level 2 for continued access to the NARSA Strains. ** Please note if you are an existing NARSA registrant, BEI Resources will contact you after the Annual Meeting with specific registration instructions and paperwork to facilitate your registration.

http://www.beiresources.org/Register.aspx

Once registered with BEI Resources, researchers will have access to the full BEI Resources catalog (within the respective Biosafety Level). The catalog has over 12,000 research reagents representing more than 400 Genus and Species focusing on NIAID's Category A, B and C priority pathogen list and Emerging Infections.

Once registered with BEI Resources, ALL investigators will receive FREE shipping and handling on orders placed through BEI Resources.

Please feel free to contact BEI Resources by email: contact@beiresources.org or by phone: Toll-free telephone number: (800) 359-7370 (8:30 AM to 4:30 PM Eastern Time) with any questions or concerns.


Schistosoma spp. Life Cycle Training Course
Highlights

General Information about the Schistosoma spp. Life Cycle Training Course

Biomedical Research Institute

12111 Parklawn Drive Rockville, MD.

May 21-23, 2014

This course is designed to acquaint investigators working in the field of schistosomiasis with basic techniques and strategies for maintaining Schistosoma mansoni, S. haematobium, and S. japonicum in the laboratory, and it offers directions into making one’s research more productive.  Among the topics covered will be procedures for setting up and maintaining the complete S. mansoni/Biomphalaria glabrata life cycle in the research laboratory, an overview of schistosomiasis, the pathology of the disease, collection of adult worms and eggs from tissues, exposure of snails to miracidia, shedding snails, exposure of mice and hamsters to cercariae, and an examination of all the intramolluscan life stages.  Hands-on exercises relating to some of these topics will also be presented (ex. perfusion of mice, exposing mice/hamsters, identification of sporocysts in snails).  Since we first began offering this basic course, over 120 scientists, technicians and students have benefited from completion of the course, and have expanded their own research agendas once back in their own laboratories.

The workshop incorporates aspects of all three Schistosoma spp. life cycles.  Attendees will be exposed to aspects of maintaining S. japonicum and S. haematobium life cycles that include general snails maintenance, collection of cercariae from infected snails, and exposing mice/hamsters.  It is our hope that incorporating the other two life cycles will encourage interest in maintaining these species in attendees’ laboratories.  The three-day course will also include a lecture on NIH-NIAID parasitology and grant programs. 

We anticipate that attendees will come away with a greater appreciation of the basic biology of Schistosoma spp. parasites, greater confidence in maintaining life cycles, and they will learn strategies for optimizing life cycles in their home laboratories.  Time will be available to ask questions about life cycle maintenance and other aspects of schistosomiasis research. There is no fee for the course.  Attendees are responsible for travel and lodging expenses, but travel assistance may be available. If you have any questions about the course, please contact me at mtucker@afbr-bri.com or (301) 881-3300 x31, or Mitzi Sereno at msereno@afbr-bri.com or (301) 881-3300 x39.


MERS-CoV Now Available to Qualifed Labs
Highlights

BEI Resources has the MERS-CoV virus (strain EMC/2012) available for distribution to qualified laboratories.  This virus will require a BEI Level 3 registration.  Middle East Respiratory Syndrome (MERS) is viral respiratory illness first reported in Saudi Arabia in 2012. It is caused by a coronavirus called MERS-CoV. Most people who have been confirmed to have MERS-CoV infection developed severe acute respiratory illness. They had fever, cough, and shortness of breath. About half of these people died.

The catalog number for the MERS-CoV virus is NR-44260. You must be logged in with a valid BEI Level 3 Account to place an order. Please email our customer service department if you have any questions about obtaining the MERS-CoV virus.


Four New Species Added to BEI Resources Leishmania Collection
Highlights

Leishmaniasis is a neglected tropical disease caused by Leishmania parasites, which are transmitted to both humans and animals by female phlebotomine sandflies. Infections take several forms, withcutaneous leishmaniasis causing skin lesions in an estimated 700,000-to-1.2 million new cases per year, and the high mortality visceral leishmaniasis resulting in fevers, weight loss and enlargement of the spleen or liver.1

Leishmania is divided into two subgenera, Leishmania and Viannia, with more than 30 known species of Leishmania further classified as New World (Western hemisphere) and Old World (Eastern hemisphere) species. Pathogenic species of both subgenera have been grouped into complexes based on phylogenetic analyses determined through differences in the natural history of their vertebrate hosts, vector specificity, clinical manifestations, geographical distribution and, more recently, using molecular approaches with different genetic markers. 2,3

A recent deposit of Leishmania strains by Dr. K. P. Chang of Rosalind Franklin University has expanded the BEI Resources Leishmania collection by four new species, L. braziliensis, L.gerbilli, L. infantum and L. turanica. Strains have been sequenced for the nagt gene, allowing for inter- and/or intra-species discrimination.4 Please refer to the individual product documentation for more information on the nagt variant of each strain.

BEI Resources No.       Product Description
NR-50600 Leishmania turanica, Strain RHO/CN/99/KMA2
NR-50601 Leishmania gerbilli, Strain RHO/CN/62/20
NR-50603 Leishmania infantum, Strain HOM/TR/03/ADANA #7
NR-50608 Leishmania braziliensis, Strain HOM/BR/75/M2903

 

References:

  1. “Leishmaniasis.” Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, https://www.cdc.gov/parasites/leishmaniasis.
  2. Schönian, G., et al. “Molecular Epidemiology and Population Genetics in Leishmania.” Med. Microbiol. Immunol. 190 (2001): 61-63. PubMed:  11770112.
  3. Marcili, A., et al. “Phylogenetic Relationships of Leishmania Species Based on Trypanosomatid Barcode (SSU rDNA) and gGAPDH Genes: Taxonomic Revision of Leishmania (L.) infantum chagasi in South America.” Infect Genet Evol. 25 (2014): 44-51. PubMed:  24747606.
  4. Waki, K., et al. “Transmembrane Molecules for Phylogenetic Analyses of Pathogenic Protists: Leishmania-Specific Informative Sites in Hydrophilic Loops of Trans-Endoplasmic Reticulum N-Acetylglucosamine-1-Phosphate Transferase.” Eukaryot. Cell 6 (2007): 198-210. PubMed:  17142569.

Image:  TEM image of Leishmania braziliensis (CDC/Cynthia S. Goldsmith, Luciana Flannery)


H7N9 Influenza Virus
Highlights

The much awaited H7N9 Influenza virus is now available for your research needs. NR-44078 is a 6:2 reassortant virus produced using plasmid-based reverse genetics to contain the hemagglutinin and neuraminidase genes from A/Shanghai/1/2013 (H7N9) and internal genes from A/Puerto Rico/8/1934 (H1N1).

Click here to see all H7N9 reagents.


Upcoming Meetings & Events
HighlightsClick Here to view our Upcoming Events Calendar.

New Website Redesign

As of Wednesday, August 20th we have updated the BEI Resources and MR4 websites to further optimize your online experience; making it easier, more accessible, and hopefully a bit more pleasurable to access your desired BEI and MR4 reagents. We have rolled out a new redesigned website that we anticipate will provide a more user-friendly navigation and shopping cart experience, easier searching and reading throughout the site, and an optimal viewing experience from essentially any web accessible platform whether it is desktop, laptop, mobile phone, or tablet.

This Responsive Web Design approach suggests that design and development should respond to the user’s behavior and environment based on screen size, platform, and orientation. As more and more of our customers in the scientific community are switching to the duality of laptops and mobile devices to conduct and support their research efforts, we at BEI Resources, would like to let our customers know… We’ve heard you… and would like to thank you for your continued feedback.

This redesigned website has been engineered to automatically respond to user preferences; switching to accommodate for resolution, image size and the scripting capabilities as dictated by the device being used. We can now make images and layouts more flexible. With this design, we have essentially eliminated the need to make individual adjustments in design and development for each new mobile device produced and made available on the market.

While Responsive Design is not a complete solution, we believe this solution provides more options for our users and a more optimal online experience overall when accessing the BEI Resources and MR4 sites; from any website accessible device; mobile or otherwise.

So feel free to access the BEI Resources and MR4 sites while in the office, lab, or on-the-go with your mobile device. An option to provide feedback is available through our Online User Feedback form, provided at the completion of your online order. Tell us what you think; we look forward to hearing from you.

At MR4 and BEI Resources, “We take care of the details - so you can focus on your research.”  

 


SARS Virus Now Available for Researchers
Highlights

We have available for the first time in the BEI Resources catalog, two SARS Coronaviruses (SARS-CoV) derived from the Urbani strain. NR-18925 is produced from a recombinant infectious clone, icSARS-CoV. NR-15418 is the mouse-adapted strain, Urbani v2163, developed by Dr. Barnard as a lethal model for evaluating antiviral agents (PubMed:19853271). To view a complete listing of all coronaviruses in the catalog, click here.


Sand Flies, Reduviids and Ticks are Here!
Highlights

BEI Resources announces the addition of Sand Flies, Reduviids and Ticks for the research community.

Catalog Number

Vector

Pathogen Competence

 

NR-43999

 Phlebotomus papatasi, PPNS, Larval

Leishmania major and Sand Fly Fever phleboviruses.

 

NR-44000

 Phlebotomus papatasi, PPTK, Larval

Leishmania major and Sand Fly Fever phleboviruses.

 

NR-44001

Lutzomyia longipalpis, LLJB, Adult

Leishmania spp. including Leishmania infantum chagasi.

 

NR-44013

Phlebotomus papatasi, PPNS, Adult

Leishmania major and Sand Fly Fever phleboviruses.

 

NR-44014

Phlebotomus papatasi, PPTK, Adult

Leishmania major and Sand Fly Fever phleboviruses.

 

NR-44015

Lutzomyia longipalpis, LLJB, Adult

Leishmania spp. including Leishmania infantum chagasi.

 

NR-42510

Ixodes scapularis

Borrelia burgdorferi, Anaplasma phagocytophilum, Ehrlichia muris-like agent, Powassan virus, Babesia spp.

 

NR-42511

Ixodes ricinus

Anaplasma phagocytophilum, Tick-borne encephalitis virus, Borrelia burgdorferi, Babesia spp.

 

NR-42512

Rhipicephalus sanguineus

Rickettsia rickettsii, Rickettsia conorii, Ehrlichia canis

 

NR-42513

Dermacentor variabilis

Rickettsia rickettsii, Francisella tularensis, Colorado tick fever virus

 

NR-42514

Amblyomma americanum

Ehrlichia chaffeensis, Ehrlichia ewingii, Panola Mountain Ehrlichial agent

 

 NR-44076 and NR-44077  Rhodnius prolixus  Trypanosoma cruzi  

CDC recommends handling naïve ticks from these species at ABSL2 containment in appropriate barrier protected facilities; pathogen research may require elevated ABSL containment. Check the BEI Vector Resources page for a list of other vectors and related reagents available through BEI Resources.


Chikungunya Viruses - Now Available for Order
Highlights

Chikungunya Viruses - Additional Strains Available

BEI Resources announces the addition of two novel BSL3 strains of Chikungunya virus (CHIKV), R-91142 and 182/25, to the catalog of available items. CHIKV is a mosquito-borne alphavirus that is mainly associated with acute febrile illness. Strains R-91142 and 182/25 CHIKV are of Asian origin. Strain 182/25 is the recently developed vaccine candidate and the only CHIKV strain to be tested in humans. Coming soon to the BEI catalogue is the CHIKV African prototype strain, S-27.

NR-13221

Chikungunya Virus, R-91142 (cell lysate)

NR-13222

Chikungunya Virus, 181/25 (cell lysate)

NR-13220

Chikungunya Virus, strain S-27 (cell lysate) Coming soon!


Resources for Trypanosome Research
Highlights

Recent acquisitions in BEI Resources aim to contribute to research focused on understanding the mechanisms of disease and the development of novel therapeutic drugs for Trypanosome research. Such acquisitions include SSGCID clones, proteins and reference parasite strains used in genome and virulence studies. For more information on the availability of these materials please contact BEI Resources customer service.

Catalog Number

Organism

Strain

Comments

NR-36197

Trypanosoma brucei brucei

STIB 247

In vivo strain, causes chronic infection in mice

NR-36198

Trypanosoma brucei gambiense

STIB 386

In vivo strain, causes chronic infection in mice

NR-36630

Trypanosoma cruzi

TcVT-1

Isolated from chagasic dog in Virginia, USA

NR-40347

Trypanosoma cruzi

Y strain (+luc)

Luciferase-expressing transgenic strain

NR-41946

Trypanosoma brucei brucei

TREU 927/4 (GUTat 10.1)

Genome strain

NR-41947

Trypanosoma congolense

IL3000

Genome strain

NR-41948

Trypanosoma brucei rhodesiense

WRATat (stock LVH/75/USAMRU-K/18) (MVAT7)

Classic strain, isolated from human patient, Kenya, 1975

NR-42009

Trypanosoma brucei

Lister 427 VSG 221

Wild type bloodstream form

NR-42010

Trypanosoma brucei

Lister 427

Wild type procyclic form

NR-42011

Trypanosoma brucei

Lister 427 VSG 221 (TetR T7RNAP)

Transgenic bloodstream form co-expressing TetR and T7RNAP

NR-42012

Trypanosoma brucei

Lister 427 29-13 (TetR T7RNAP)

Transgenic procyclic form co-expressing TetR and T7RNAP


BEI Resources Fungi Repository is Growing!
Highlights

 

BEI Resources is working to expand the fungal resources so that researchers have a broader range of organisms and reagents for their work.  BEI Resources currently has eight genus and species represented with several more currently going through the production pipeline.  BEI Resources is actively encouraging depositors with medically relevant strains to deposit into the repository. If you are interested in depositing, please click here.


Cloned lines of Toxoplasma gondii are now available from BEI Resources
Toxoplasma gondii is an obligate intracellular protozoan parasite of the phylum Apicomplexa that is the causal agent of toxoplasmosis. T. gondii is dominated by three widespread clonal lineages, referred to as types I, II, and III. The three major Toxoplasma lineages differ in a number of phenotypes, the best described of which is virulence in mice. Recent studies have examined the genetic basis for these differences by mapping virulence in F1 progeny derived from crosses between the different T. gondii lineages.
 
BEI Resources houses various cloned lines selected from progeny of two parallel genetic crosses between a Type II parental strain (ME49 clone B7; NR-10150) and a Type III parental strain (CEP; NR-10151). Authentication of individual clones is performed through phenotypic and genotypic testing. This includes drug susceptibility to adenine arabinoside (ara-A) and sinefungin (Fig. 1) and PCR-based analysis of the SAG1 and KT-850 loci (Fig. 2).
 
Additional cloned lines from a Type I and Type III genetic cross will be available soon. In addition, BEI Resources offers more than 50 types of polyclonal antibodies to various Toxoplasma proteins. For technical questions about these products, or to learn more, please contact us by clicking here.

ATCC Adds ISO Guide 34:2000 and ISO 17025:2005 Accreditation to the ISO 9001:2000 Certification
ATCC (American Type Culture Collection), the contract manager of BEI Resources, has announced its accreditation for ISO Guide 34:2000 and ISO 17025:2005, an international multi-industry standard specifically designed for producers of reference materials.

The ISO Guide 34 accreditation by the American Association for Laboratory Accreditation (A2LA) builds upon the earlier certification for compliance with the ISO 9001:2000 standard for quality management systems received by ATCC in 2007. Biological reference materials produced under an ISO Guide 34-accredited process have confirmed identity, well-defined characteristics and an established chain of custody — qualities essential to their effectiveness as biological standards in research and development.

In gaining ISO recognition, ATCC joins a pioneering group of biological product organizations with ISO certification. Biological materials authenticated and preserved by ATCC, such as cell lines and microorganisms, are widely used as reference materials for research and product testing.
 
ATCC Senior Director for Quality, Compliance and Biosafety Barry Waters, PhD, remarked,“ISO 34 accreditation represents an objective measure of confidence in the consistency and quality of ATCC reference cultures. It expands ATCC’s ability to produce internationally recognized standards for biological research and development, including certified reference materials (CRMs).”
 
ISO 17025:2005 sets general requirements for the competence of laboratory testing and assures customers that the characterization and purity protocols used in the manufacture of products are precise, accurate and have repeatability.  The scope of the accreditation includes specific tests or properties measured for microbial and cell cultures.

ISO 9001:2000 for quality management systems, ISO Guide 34 for reference material production and ISO 17025 for laboratory testing are among the standards promulgated by the International Organization for Standardization (ISO), a network of national standards institutes from 157 countries. ISO operates a Central Secretariat located in Geneva,Switzerland to coordinate the system.

The BEI Resources Website got a Make Over!
HighlightsWatch Video

 

BEI Resources is pleased to announce a new and improved website!  We heard your feedback concerning difficult searches and long checkout times…and, we invite you to explore and discover our new dynamic search package, state-of-the-art shopping cart experience and enhanced product information pages for your items on interest.

 

Our new search engine provides the community with a user friendly interface in which to research, search, and order reagents. We will now be using the same search and navigation features of many of the world's largest internet sites. Some of the major search features include dynamic filter searching, Intuitive Auto-Complete Text Searches, Suggested Search Terms, Dynamic Clustering and multiple sorting parameters for result sets.

 

Your ordering experience is also vastly improved with our new Web Services E-Commerce software.  No more waiting for your items to load to the shopping cart; with the new software, your checkout is fast and reliable. Look for all these updates today!


Diarrheagenic E. coli organism panels
Outbreaks of foodborne disease caused by E. coli bacteria have become a serious problem in this country. E. coli organism panels, genomic DNA, and technical information are now available to support research to detect, treat, and prevent foodborne diseases.

In February of 2008, BEI Resources released the organism panel (NR-9545) composed of representatives of the diarrheagenic E. coli pathotypes ETEC, EHEC, EPEC, EIEC and EAEC available for ordering. Genomic DNA panels from these organisms are also now available (NR-9546).

Supporting documentation includes strain propagation information and growth and morphology on certain selective and differential microbiological media (see figure to the right).
 
For technical questions about these products or to learn more, please contact our Technical Services Department.

M. tuberculosis knockout clone pools and companion DeADMAn microarray are now available
Highlights
Dr. William Bishai , Dr. Gyanu Lamichhane, and colleagues from the Tuberculosis Animal Research and Gene Evaluation Taskforce (TARGET), supported by NIH/NIAID contract N01-AI30036 awarded to the Johns Hopkins University, have generated twenty M. tuberculosis knockout clone pools to facilitate analyses of gene function under in vivo conditions of interest to researchers. In addition, they collaborated with Dr. Robert Fleischmann and Dr. Scott Peterson and colleagues from the Pathogen Functional Genomics Resource Center, supported by NIH/NIAID contract N01-AI15447 awarded to the J. Craig Venter Institute, to develop the DeADMAn Microarray Version 1.0 as a complimentary reagent for use with the knockout clone pools.
 
One or more M. tuberculosis knockout clone pools containing genetically defined transposon mutants of interest (input pool) are used to infect an animal that is subsequently subjected to a stress condition.  Mutants from the input pool and those recovered from the stressed animals (output pool) are identified by amplification of unique transposon junction sequences of each mutant.  The competitive hybridization of the input and output pools to the DeADMAn microarray allows for the easy detection of mutants in the input pool and missing from the output pool. The 20 M. tuberculosis knockout clone pools (NR-15773 to NR-15792) and the DeADMAn Microarray Version 1.0 (NR-18958) are now available from BEI. 

New Monkeypox Virus Real-Time PCR Assay Discriminates Monkeypox Viruses from other Orthopox Viruses
Monkeypox virus is transmissible to people and it has become the most important Orthopoxvirus infection in human beings since the eradication of smallpox in 1970s.
 
A Monkeypox Virus quantitative PCR assay (Figure 1) which preferentially detects Monkeypox viruses is now available through BEI Resources (NR-9351). This assay detects Monkeypox viruses at least 1000 fold more efficiently over most other Orthopox viruses or non-Orthopox viruses (Figure 2). Since Monkeypox virus and Vaccinia share considerable homology it is a critical advantage that this assay can detect Monkeypox strains at a minimum of 100 fold more efficiently over the other Vaccinia strains.
 
The qPCR Monkeypox assay includes the following components: primers, FAM labeled probe, and plasmid for a standard curve. Each vial of reagent can be used for approximately 96 reactions. For technical questions about this assay or to learn more, please contact our Technical Services Department.     

Recombinant B. anthracis spore proteins and polyclonal antibodies are now available
Highlights
Bacillus anthracis are gram positive, spore-forming bacteria. The B. anthracis spore is covered with a balloon-like exosporium that is made up of multiple proteins including the immunodominant glycoprotein Bcl-A (1, 2). Current vaccine strategies have targeted the protective antigen (PA) protein which is an essential component of both lethal toxin and edema toxin. However, vaccines based on immunization with PA alone can result in varied levels of protection in the host (3). More recent research has suggested that an improved protective effect can be achieved by immunizing animals with a combination of PA and other proteins present in the exosporium when compared to immunization with PA alone (1, 4).
 
BEI Resources has just released recombinant exosporium proteins along with their complementary rabbit polyclonal antibodies. Each protein has been shown experimentally to react with the anti-spore polyclonal antibody 31101-01 (1). In addition, immunization of mice with the hypothetical protein p5303 or the structural protein BxpB in combination with PA showed enhanced protection against spore challenge (1).

Localization of B. anthracis spore proteins within the spore by immunoelectron microscopy. Spores were labeled, following embedding in 4% formaldehyde, by incubation with A) NR-10436 anti-GerQ polyclonal IgG, or B) anti-p5303 polyclonal IgG followed by a gold-labeled secondary antibody (1).

For technical questions about these products, or to learn more, please contact us by clicking here.
 
Recombinant Protein
Polyclonal Antibody
NR-9577 Collagen-like protein BclA
NR-9578 Polyclonal antibody to BclA
NR-10435 BA5641 Spore coat protein GerQ
NR-10436 Polyclonal antibody to GerQ
NR-10505 BA4499 Superoxide dismutase SODA1
NR-10506 Polyclonal antibody to SODA1
NR-12128 BA1489 Superoxide dismutase SOD15
NR-12129 Polyclonal antibody to SOD15
NR-12130 BA5699 Hypothetical protein p5303
NR-12131 Polyclonal antibody to p5303
NR-12132 BA1237 Hypothetical exosporium protein BxpB
NR-12133 Polyclonal antibody to BxpB


 
































References:
1. Cybulski, R.J., Sanz, P., McDaniel, D., Darnell, S., Bull, R.L., and O’Brien, A.D. Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen. Vaccine 2008;26:4927-4939.
 
2. Sylvestre, P., Couture-Tosi, E., and Mock, M. A collagen-like surface glycoprotein is a structural component of the Bacillus anthracis exosporium. Mol Microbiol 2002;45(July(1)):5240-7.
 
3. Fellows, P.F., Linscott, M.K., Ivins, B.E., Pitt, M.L., Rossi, C.A., Gibbs, P.H. et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001:19(April(23-24)):3241-7.
 
4. Brahmbhatt, T.N., Darnell, S.C., Carvalho, H.M., Sanz, P., Kang T.J., Bull, R. L., et. al. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect Immun 2007;75 (November (11)):5240-7.

Ferret Reagents available through BEI Resources
In recent years, the ferret has proven to be an excellent animal model for the study of pathogenicity and transmissibility of influenza viruses (Journal of Virology 81 (13): 6890-9898 (July 2007)). Even the attachment of highly pathogenic avian influenza H5N1 in the lower respiratory track of humans is mimicked in the ferret model (Science 312 (5772): 5772 (April 21, 2006)). In like manner, ferrets are also being shown to be a good model for SARS research because they are susceptible to infection by the SARS coronavirus and can transmit the virus to uninfected animals (Nature 425: 915 (October 30, 2003)). 

To support the research on these emerging infections, BEI Resources (under the direction of NIAID) will soon offer a vast array of tools for the use of the ferret model. In February of 2008, BEI Resources made available approximately 100 ferret immune gene primers that were produced under contract by the laboratory of Dr. David Kelvin (Head, Division of Experimental Therapeutics, University Health Network). In Spring 2008, BEI Resources will also offer a number of monoclonal antibodies against ferret immune antigens, also from Dr. Kelvin’s laboratory.

Immortalized murine macrophages and microglial cell lines from TLR knockout mice available
The Toll-like receptor (TLR) family is the essential recognition and signaling component of multicellular organisms against all the major classes of pathogens. The study of TLR signaling pathways has become a productive area of investigation for researchers interested in signal transduction during innate immunity and inflammation. Of interest to biodefense, the identification of TLRs, their ligands, and signaling events will provide insight into understanding the role of the innate immune response in infectious diseases such as anthrax, plague, tularemia, and smallpox. Knockout mice for many of these innate immune receptors and adaptor molecules are not always widely available. In addition, generation of such knockout animals requires significant human and economic resources. 

BEI Resources houses a number of immortalized macrophage cell lines from knockout mice deficient in TLRs and their signaling molecules. Characterization of the immortalized cell lines has shown a deficiency in the production of cytokines upon stimulation with defined differential TLR ligands using ELISA (Fig. 1). Use of this resource will enable the investigation of immune mechanisms against pathogens and evaluation of pharmacological agents. For a list of available cell lines or technical questions about these products, please contact us by clicking here.

Fig. 1. Secretion profiles of TNF among immortalized cell lines derived from knockout mice lacking the TLR adaptor molecules MAL/TIRAP and MyD88. Cells were stimulated with increasing concentrations of ligands against TLR2/6 (Pam2), TLR3 (PolyIC), and TLR4 (LPS). A, cytokine secretion in wild type and MAL/TIRAP -/- macrophages. B, cytokine secretion in wild type and MyD88 -/- microglial cells.

Epsilon Toxin Reagents are now Available from BEI Resources
Clostridium perfringens are gram positive, obligate anaerobes that produce multiple toxins. Type B and D strains, responsible for necrotic enteritis or enterotoxemia in animals, express Epsilon toxin encoded by the etx gene. This protein exerts its cytotoxic activity on sensitive cells by forming pores in the cell membrane resulting in a loss of cellular homeostasis.  Epsilon toxin is a USDA and HHS select agent toxin and is included on the NIAIDlist of Category B priority pathogens.
 
BEI Resources has reagents that can be used to study the molecular mechanisms of Epsilon toxin cytotoxicity. NR-856 is native Epsilon protoxin purified directly from C. perfringens culture supernatant. NR-4670, the native protoxin that has been activated using trypsin, is cytotoxic to ATCC® CCL-34™ MDCK cells (Figure B). In addition, we offer NR-865 polyclonal antibody to Epsilon toxin which can detect the protein in an ELISA or western blot format.

Fluorescence micrographs showing MDCK cells treated with NR-4670 activated Epsilon toxin (B) or without toxin (A) for 1.5 hours in the presence of propidium iodide. Pore formation by the toxin is demonstrated by the uptake and fluorescence of propidium iodide compared to the untreated control.

For technical questions about these products, or to learn more, please contact us by clicking here.

Yersinia pestis Plasmid Profiling Assay is Now Available

The agent of bubonic plague Yersinia pestisis a NIAID Category A Priority Pathogen and likely biothreat. In support of research and product development in this area BEI Resources released a Yersinia pestis Plasmid Detection Kit (NR-9562) in April 2008.   

This assay allows the researcher to quickly identify the presence of plasmid-encoded virulence factors pPCP1, pMT1 and pCD1 and is designed to be used for characterization purposes in conjunction with standard microbiological techniques.

 

The assay consists of primer sets designed to specifically detect the pPCP1, pMT1 and pCD1 plasmids using standard polymerase chain reactions and includes a species-specific positive control primer set and internal positive control template.

 

PCR amplification of genomic DNA from Yersinia pestis displaying a pPCP1+, pMT1+, pCD1– profile (lanes 2-4 respectively). Lanes 5 and 6 are the Yersinia pestis and internal positive controls. Lane 7 is a non-template control."

 

Panel A. Growth of Yersinia pestis on Congo Red media showing red/orange colonies typical of pgm+ organisms. Organisms that are confirmed pgm+ and pCD1+ are considered Select Agents.

 

Panel B. Bacteria lacking pgm showing distinctive variations in colony morphology and reduced coloring on Congo Red media as compared to pgm+ organisms.

 

For technical questions about these products or to learn more, please contact our Technical Services Department.


BEI Resources offers Overlapping Peptide Arrays for Pathogens
Custom peptides have many uses in biotechnology including epitope mapping, analyzing protein-protein interactions, and as antigens for the generation of anti-peptide antibodies. For epitope mapping, arrays consisting of a small amount of a large number of overlapping peptides are required. For the individual researcher, the generation of such a custom array of overlapping peptides for specific proteins of interest could be cost-prohibitive. For that reason, NIAID has funded BEI Resources to generate a substantial number of peptide arrays related to applications in biodefense and emerging infections. These reagents are provided free of charge (except for shipping and handling fees) for use by BEI registrants.

Currently BEI Resources offers peptide arrays for proteins of influenza, SARS-CoV and human coronaviruses, dengue virus, hepatitis C virus, West Nile virus, hantavirus, vaccinia virus, Yersinia pestis, and Bacillus anthracis (complete list). For more information on these peptide arrays, please search our online catalog for your peptide array of interest. If you need more assistance or information about BEI Resources peptide arrays, please contact us by clicking here.

BEIRESOURCES.ORG

Home Site Map Knowledge Base (FAQs) Privacy Policy

Careers Contact Us Terms of Use Accessibility policy

DOWNLOAD READERS

Download Adobe PDF ReaderAdobe Reader Download Microsoft PowerPoint ViewerMicrosoft PowerPoint Viewer Download Microsoft Word ViewerMicrosoft Word Viewer Download Microsoft Excel ViewerMicrosoft Excel Viewer

CONTACT US

Call Us Toll-Free:(800) 359 - 7370 E-mail: contact@beiresources.org TTY:(703) 365 - 2727 (for deaf, hard of hearing, or speech impaired)

BEI Resources is funded by the National Institute of Allergy and Infectious Diseases and managed by ATCC
ATCC. All Rights Reserved.
About Trust Online View Full Site
ATCC Logo
top
Text Version
Low Bandwidth